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SUMMARY
This dissertation presents analysis of various features of cases of canine
osteosarcoma (including one case of chondrosarcoma) managed in the
D epartm ent of Veterinary Surgery, Glasgow University Veterinary School.
These features include:
• the clinical outcome in cases managed with surgery and cisplatin 
chemotherapy
• experiences with the use of bone allografts for limb reconstruction following 
en bloc resection
• analysis of certain aspects of the pharmacokinetics of the drug administered 
to selected patients
These findings are presented in the light of published work on the
treatm ent of osteosarcoma and the use of cisplatin in the dog and man.
The major conclusions are:
• subsets of the tum our may exist, with the potential for varying biological 
behaviour
• the management of osteosarcoma with cisplatin chemotherapy has a positive 
benefit on survival, in selected patients, but death due to metastatic disease is 
almost inevitable
• the design of chemotherapeutic protocols for canine osteosarcoma is not 
finalised
• though the area under the platinum in plasma ultrafiltrate concentration-time 
curve gave a consistent value in the clinic at Glasgow University Veterinary 
School it is not suitable, in isolation, for comparing adm inistration protocols
• the use of massive allografts in conjunction with cisplatin chemotherapy 
requires further evaluation
• multi-centre prospective trials would be the way to pursue these goals
INTRODUCTION
Osteosarcoma is the commonest primary bone tumour in the dog. It 
represents approximately 80% of all primary bone tumours with the remaining 
cases divided principally between chondrosarcoma (10%) and haemangiosarcoma 
and fibrosarcoma (7% combined) (Goldschmidt and Thrall 1985a). It accounts 
for between 2-7% of all canine tumours, affecting around 8-10,000 dogs per year, 
in the USA (LaRue and Withrow 1989). This is high compared to the incidence in 
the human population (approximately 1000 cases per year in the USA). As a 
consequence of this high incidence in the dog compared to man, and the similar 
biological behaviour, it has been identified as an animal model of the human 
disease (Brodey and Riser 1969, Misdorp 1980, Pierrepoint 1985, Straw and others 
1990, Withrow and others 1991).
Osteosarcoma is a devastating condition in both the canine and human 
patient. It is characterised by the destruction of the local bony architecture with 
associated dysfunction and early metastasis resulting in a high mortality rate.
Treatm ent of the condition presents two major challenges for the clinician:
• Control of local disease and maintenance of function
• Control of disseminated disease
It is generally believed that in both species amputation or tum our resection 
alone is palliative, having no effect on the development of metastatic disease. 
Few dogs apparently cured by am putation have been reported (Brodey and Riser 
1969, Spodnick and others 1991).
Though amputation is acceptable in smaller dogs with a good functional 
result it is not ideal in the large and giant breeds. In man a num ber of surgical 
approaches are advocated. These include amputation or resection and
reconstruction with an allograft or endoprostheses.
The use of chemotherapeutic agents has shown beneficial effects in delaying 
of development of metastatic disease in man have been shown (Yasko and Lane 
1991). These techniques have not proved as useful in the dog (Madewell and 
others 1978, Jeglum 1985). However, some beneficial effects have been
demonstrated. Currently the drug receiving most attention for the treatm ent of 
osteosarcoma in the dog is diamminedichloroplatinum (II) (cisplatin).
CHAPTER 1
TUMOURS OF THE SKELETAL SYSTEM OF THE 
DOG:
REVIEW OF CLASSIFICATION AND BEHAVIOUR 
WITH AN OVERVIEW OF MANAGEMENT IN MAN 
ANDTHE DOG
Chapter 1
PRIMARY SARCOMAS OF BONE
A sarcoma is defined as a malignant neoplasm derived from mesenchymal 
tissues (Dubielzig 1989). These tissues are derived from the mesoderm, which is 
the third germ layer of the embryo. M esoderm gives rise to the blood and 
lymphoid tissues and also to the connective tissues including the general supportive 
tissues (fibrous and adipose) and the more specialised tissues (bone and cartilage) 
(Leeson and Leeson 1979). Bone is an organ of connective tissues. These cell 
types range through the general supportive connective tissues (fibrous and 
adipose), haematological tissues (endothelial and and cell precursors) to the more 
specialised connective tissues of bone and cartilage (Pool 1990).
Nine basic types of primary bone sarcoma are described. These are 
summarised in Table 2 (page 3). Osteosarcoma is heterogeneous in nature. A 
tumour containing neoplastic osteoid, whether mineralised or not, is by definition 
an osteosarcoma. However, there may be significant proportions of other matrix 
products such as neoplastic cartilage within the tumour mass. Oteosarcoma is 
classified depending on the proportion of cell types and matrix it contains (Pool 
1990) (Table 1, page 2). The distribution of osteosarcomas within the canine 
skeleton is summarised in Figure 1, (page 4). Certain regions are over 
represented.
Osteosarcoma type Characteristics of histopathology
osteoblastic predominantly neoplastic bone
chondroblastic predominantly neoplastic cartilage
telangiectatic cells produce osteoid but there are attempts 
at the development of vascular channels 
(resembling haemangiosarcoma)
fibroblastic neoplastic fibrous stroma with little osteoid 
or neoplastic bone
combined type mixed matrix but no dominant pattern
poorly differentiated cell morphology difficult to classify but 
tumour osteoid and bone present
Table 1. Subdivision of osteosarcomas by nature of matrix.
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Distinguishing features
osteosarcom a
chondrosarcoma
fibrosarcoma
haemangiosarcoma
liposarcoma
undifferentiated sarcoma
giant cell tumour or 
osteoclastom a
myeloma
lymphoma
(previously referred to in the 
literature as reticulum cell 
sarcoma, Jeglum 1985)______
cells produce osteoid, not 
necessarily mineralized
characterised by the production 
of neoplastic cartilage, there 
may be areas of calcification 
these are not areas of osteoid 
bone also may develop in 
chondrosarcomas by 
endochondral ossification (Pool 
1978)
cells produce varying amounts of 
collagenous matrix
areas of undiffereniated sarcoma 
with areas of primitive vascular 
channels
fat may be demonstrated within 
the tumour cells
cell types very primitive with 
insufficient organization to 
produce recognisable matrix
large numbers of giant cells 
care must be taken as giant cells 
are a common feature of the 
histopathology of many bony 
lesions including osteosarcoma 
and also of som e benign lesions 
(Pool 1978)
population of neoplastic plasma 
cells
population of neoplastic 
lymphocytes
Table 2. Classification of primary bone sarcomas in the dog.
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The type of sarcoma found varies with the region of the skeleton. 
Chondrosarcoma is far commoner in the axial skeleton than the appendicular and 
for osteosarcoma the converse is true. It is more difficult to generalise about the 
other tumours because of their infrequent occurrence. Sarcomas may arise in any 
part of the bony structure. However, in the canine long bone they almost 
exclusively originate in the medullary cavity (Pool 1990).
Rare periosteal or juxtacortical (arising from the periosteal region) 
osteosarcomas and chondrosarcomas are described (LaRue and Withrow 1989).
Sarcomas arising from bones of the skull have posed a problem for 
pathologists in classification. Some benign conditions can be confused with 
neoplasia (e.g., craniomandibular osteopathy, Riser and Newton 1985) by 
inexperienced veterinary or uninitiated non-veterinary pathologists.
2.3%
3.1%
3.2%
3.2%
5.4%
8.5%
7.5%1.6 %
23.1%
.2 %
1. 8 %
2 .6 %
Figure 1. Distribution of osteosarcoma in the canine skeleton from the records of 
1215 cases (Goldschmidt and Thrall 1985a).1
True osteosarcomas of the skull do occur albeit infrequently (Figure 1, page 
4). A morphologically distinct tumour occurs in the skull region alone that has a 
distinctive multilobulated pattern. This has been referred to by many names in 
the past (e.g., canine aponeurotic fibroma, chondroma rodens, multilobular
illustration  reproduced with permission of the publishers. In: Textbook of Small Animal 
Orthopaedics (1985) (Eds. Newton and Nunamaker), Philadeplphia, J.B. Lippincott and Company, 
page 888, Figure 74-1.
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osteom a and chondroma Straw and others 1989). Currently the tumour is referred 
to as multilobular osteochondrosarcoma by Straw and others (1989) but Pool 
(1990) suggests the term multilobular tum our of bone. Though it has similarities 
with appendicular osteo- and chondrosarcoma there are differences in cell 
morphology and behaviour (Pool 1990). Though usually described as benign, a 
recent review has suggested metastasis in 58% of cases and it is perhaps better 
thought of as a malignant tumour (Straw and others 1989).
FUNCTIONAL CLASSIFICATION
The classic histological descriptions of osteosarcoma give a description of 
the cellular components of the tumour. However, the behaviour is not well 
correlated with the basic histological appearance (Rosen 1987). Histological 
diagnosis alone is limited in that it does not take account of the extent of the 
disease in the patient.
Several methods have been developed to describe and stage neoplasms in 
an effort to improve management decision making and refine the prognosis. 
These methods include other features of the tumour and the patient as a measure 
of progression. The World Health Organisation has developed the TNM  system. 
This was originally developed for the classification of human tumours to allow 
meaningful comparison between the work of different clinical centres. It is known 
as TNM  system because it is based on recording features pertinent to the tumour, 
lymph nodes and assessment of the extent of metastasis.
T stage of primary tumour
N stage of local lymph nodes
M the absence or presence of distant metastasis
The important features of this system in relation to bone tumours in dogs 
are shown in Table 3 (below).
Grade Description
Tumour TO no evidence of tumour
T1 tumour confined within the
medulla and cortex
T3 tumour extends beyond
periosteum
Metastasis MO no evidence of distant
metastasis
M l distance metastasis detected
Table 3. World Health Organisation staging criteria for skeletal sarcomas2
2Owen 1980, quoted by Withrow and McEwan 1989.
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The local lymph node status is not described for this tumour because of the 
low rate of metastasis to regional lymph nodes (<5% , Pool 1990). Lymph nodes, 
however, may be increased in size in response to the inflammatory reaction 
associated with the tumour (Straw and others 1991). Invasion of the lymphoid 
system occurs late in the disease and is thought to be of little clinical importance 
(Pool 1990). In man, this is thought to be a result of the lack of lymphoid drainage 
of the intramedullary bone (Robertson and others 1984).
A staging system more specific to musculoskeletal tumours was described by 
Enneking for use in humans (Table 5, page 8). Evaluation of this system in 
humans has demonstrated reasonable correlation with long term prognosis (Lane 
and Glasser 1987). This system has been used in the veterinary literature for the 
description of patients but has not yet been related to outcome. Some authors 
have the subjective opinion that there may be differences between the behaviour of 
the morphologically classified canine osteosarcomas (Misdorp 1980, Gleiser and 
others 1981) in the way there appears to be in humans. However, the consensus is 
that a relationship has yet to be demonstrated in the dog (Straw and others 1990). 
In man classification of bone sarcomas on histological grounds has been further 
advanced by dividing them into three broad categories (Table 4) (Rosen 1987).
Cell type Histological appearance
small cell small, round, undifferentiated
spindle cell more differentiated with spindle
appearance
pleomorphic elements of the other two categories
Table 4. Categories of cell type used to classify sarcomas in man (Rosen 1987)
This is irrespective of the conventional histological subgroups. Use of this 
system assists with therapeutic decisions and correlates with the variation in 
behaviour that is observed.
These tumour cell types broadly exhibit common behaviour and response to 
therapy. This is summarised in Table 6 (page 9). The range of bone pathology in 
the dog is limited compared to man, with small cell carcinomas of bone in 
particular being very rare (Brodey and Riser 1969).
Examples of small cell sarcomas in man are Ewing‘s sarcoma (not recorded 
in the dog), some forms of osteosarcoma (rare), chondrosarcoma, liposarcoma and 
neuroblastoma. That these unusual osteosarcomas are not aberrant forms of 
Ewing‘s sarcoma was confirmed by Fellinger and others (1991) using 
immunohistochemical techniques.
6
Chapter 1
Canine tumours are not routinely classified according to this system at 
GUVS or apparently in the general veterinary oncological literature. However, it 
is felt that this system could be adapted to the classification of sarcomas in 
domestic animals though it is not certain that it would prove to be as useful 
(McCandlish^, personal communication).
Osteosarcomas are often described in some of the veterinary literature as 
being of high or low grade. This distinction between high and low grade is a 
subjective assessment based on cell morphology, frequency of mitotic cells and the 
level of cell differentiation. The more pleomorphic, the greater the numbers of 
mitotic cells and the less well differentiated the cells are the more aggressive or 
high gade the the tum our is assessed to be. Most canine tumours are described as 
moderately or severely anaplastic (Withrow and others 1991).
Flow cytometry, a technique that quantifies the amount of DNA in cells, 
can be used to subdivide tumour types. Using this technique, subsets of human 
osteosarcoma have been shown to have different metastatic potential. The more 
deranged the DNA content the less likely was metastasis (Mankin 1987a). On 
analysis, human and canine osteosarcomas show similar characteristics (Withrow 
and others 1991). Analysis of canine osteosarcoma and its metastatic deposits 
have shown that metastatic clones may be derived from more than one cell (Fox 
and others 1990).
3Dr. I.A.P. McCandlish, Department of Veterinary Pathology, Glasgow University Veterinary School
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Chapter 1
Newer techniques involving the use of monoclonal antibodies are becoming 
available for use in the classification of sarcomas4. These should help to define 
the origin of these tumours by enabling one to work back from the tumour to the 
original cell type. They also may help in the classification of sarcomas into groups 
that have similar responses to therapy and prognosis by identifying related types.
BEHAVIOUR OF OSTEOSARCOMA 
Local
Initially the clinical picture is of local inflammation with heat, swelling and 
pain over the affected region. This often presents as an acute exacerbation of a 
chronic, progressive, low grade lameness. Initially swelling may be minimal and 
with the more proximal tumours may be very difficult to appreciate.
Local effects are at first destruction of medullary and cortical bone. As the 
tum our extends through the cortex the periosteum is stripped from the bone 
surface, contributing to the pain experienced (LaRue and Withrow 1989).
Surrounding the neoplastic area there is an area of intense inflammation, 
which presumably also contributes to the discomfort. Extension into the joint is 
rare but will develop occasionally in long standing tumours.
Pathological fracture, as the result of the weakening of the bony 
architecture, may occasionally occur. W here there has been acute exacerbation of 
a relatively low grade lameness this may be related to local micro-fractures. The 
term  "pathological fracture" is usually retained for full cortical disruption. 
Fracture in cases of tumours of the axial skeleton may result in the sudden onset of 
neurological signs following collapse of the vertebrae and spinal cord compression.
Animals with long standing metastatic pulmonary disease may develop 
hypertrophic pulmonary osteopathy - a proliferative disorder of the periosteum. 
Though the aetiology is uncertain this is thought to be mediated by a neurovascular 
mechanism as it can be treated successfully by vagotomy (Ogilvie 1989).
Distant
Osteosarcomas are recognised to be metastatic. The primary route of 
metastasis is haematogenous, probably via the loose endothelial junctions in the 
bone marrow sinusoids (Pool 1990). Metastasis in the first instance is usually to 
the lungs. Metastasis to regional lymph nodes occurs rarely. The incidence of 
pulmonary metastasis is 10% based on radiographic evaluation and 45-65% at post 
m ortem  examination (Pool 1990). Lui and others (1977) described the incidence 
of pulmonary metastasis at post mortem as 9/73 cases (12%) (the timing of these
4Professor N.T. Gorman, Department of Veterinary Surgery, Glasgow University Veterinary School
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examinations ranged from the time of diagnosis to 25 months post surgery). 
Interestingly about half of the metastatic deposits mimic the physical appearance 
of the primary (Pool 1990).
The incidence of metastasis to other organs in untreated animals is low 
(Pool 1990). Metastasis to the other parenchymatous organs (liver, kidney, 
spleen) is occasionally observed. Metastasis to other areas is rare. There is one 
case report of metastasis to the eye (Render and others 1982).
Metastasis to bone is unusual in untreated cases (Pool 1990). Lui and 
others (1977) observed this in only 3/73 of their cases. Assessment with other 
techniques has revealed an instance of 3-19% (scintigraphy, Lamb 1991) and 6.4% 
(radiographic skeletal survey, Straw and others 1990).
This distribution may be a function of time. Presumably as the tumour 
cells are released into the venous circulation the majority will become lodged in 
the pulmonary tissue (either physically or in relation to the mononuclear phagocyte 
system).
Animals that undergo management by amputation alone demonstrate a 
higher rate of metastasis to other organs (Brodey 1965, Brodey and Riser 1969, 
Brodey and Abt 1976, Lui and others 1977). The reason for this is uncertain. The 
primary is usually controlled adequately by removal of the affected quarter. The 
development of these aberrant deposits, after the removal of the primary, suggests 
that they were present before amputation or that they represent spread from 
pulmonary metastasis.
The pattern of metastasis may vary with the region of the skeleton. 
Osteosarcomas of the skull are described as having low rates of metastasis (Pool
1990). Parosteal sarcomas, though rare are thought to metastasise late (LaRue 
and Withrow 1989). Misdorp (1980) feels those of the hind limb are relatively 
more aggressive.
The other primary sarcomas of bone are also locally aggressive and 
metastatic but the patterns vary. Their relative rarity makes establishing their 
behaviour difficult. They are summarised in Table 7 (page 12).
Myasthenia gravis has recently been reported in association with 
osteosarcoma (M oore and others 1990) in three cases. Myasthenia gravis as a 
para-neoplastic syndrome in cases of thymoma is well-documented in the dog and 
man (Crow 1989). One of the reported cases associated with osteosarcoma had 
received an intensive course of cisplatin chemotherapy and another developed 
myasthenia 5 years before the tumour. It is difficult to attribute either of these 
cases directly to the tumour. If myasthenia is truly a problem, it may become 
more prevalent as the management of cases changes.
11
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Tumour Behaviour
chondrosarcoma clinical course tends to be longer with late and lower
rate of metastasis (Lui and others 1977) 
haemangiosarcoma very destructive before clinical signs develop often with
metastasis at the time of diagnosis 
fibrosarcoma relatively rare as a primary bone tumour but there is an
impression that it metastasises late in common with 
other fibrosarcomas
Table 7. Behaviour of the central non-osteogenic primary bone sarcomas
compared to osteosarcoma.
SIGNALMENT OF DOGS DEVELOPING OSTEOSARCOMA
The signalment of the reported cases of osteosarcoma are summarised in 
Table 9 (pages 16-17). The majority of animals affected by osteosarcoma are the 
medium, large and giant breeds of dog. The largest survey is of 1215 cases 
(collected by Brodey, analysed by Kisler and quoted by Goldschmidt and Thrall 
1985a). In this survey 95% of affected individuals were 14kg or greater in weight. 
This weight distribution has been observed by other authors. There was a slight 
preponderance for males though this may be breed related (in Saint Bernards this 
appears to be reversed).
Certain breeds appear to be over represented including the Irish setter, 
Saint Bernard, G reat Dane, rottweiler, and German Shepherd dog. Some of this 
may be related to body size, however, a familial tendency has been demonstrated 
in some breeds (see Table 11, page 19) and these breeds have also been over 
represented in some other surveys. The distribution of tumours also appears to be 
related to body size with tumours of the axial skeleton being a feature of small 
breeds (Table 9, page 18).
RISK FACTORS AND AETIOLOGY
The aetiology of primary bone tumours is unknown (LaRue and Withrow 
1989). However, examination of the circumstances in which primary bone 
sarcomas are found has identified some common features (Table 11, page 19).
Primary bone tumours can be induced by irradiation either experimentally 
or as a consequence of radiotherapy for another neoplasm (Thrall and others 
1983). Experimental exposure to radioactive compounds may also induce
12
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osteosarcomas (LaRue and Withrow 1989). This is of particular interest as 
strontium, one of the implicated elements, is a feature of radioactive fall out and is 
concentrated in the growing bones of young animals and children. There is no 
evidence that radiation is a factor in spontaneous disease (Owen 1986).
A number of family lines of rottweilers and Saint Bernards have been 
identified with a higher than expected incidence of osteosarcoma development. It 
could be speculated that there was vertical transmission of an infectious factor. 
Alternatively, a heritable inability to suppress osteosarcoma development is 
possible, though excessive tumour development in general was not a reported 
feature of the affected animals. A nother possibility is a heritable abnormality of 
the affected cell line(s) resulting in more frequent malignant transformation.
Osteosarcoma has been transmitted experimentally by injection of puppies 
with tumour cells (LaRue and Withrow 1989). This led to speculation of a viral 
aetiology though this has not been demonstrated. Type C virus particles have 
been demonstrated in naturally occurring giant cell tumours in cats (McGlennon
1991). Their significance is unknown and these tumours are exceedingly rare.
Most spontaneous osteosarcomas, and sarcomas of the medullary canal, 
occur in the region of the metaphyseal scar. Though this was previously an area of 
intense bony activity, in the typical canine osteosarcoma patient it is quiescent. In 
the typical human patient it is still an active area. In an examination of normal 
growth of the distal radius and ulna in G reat Danes, isolated islands of growth 
plate cartilage were found embedded in the growing diaphyseal bone (Riser and 
Shirer 1965). Their fate is unknown but these "unfulfilled" cells are suggested as a 
potential source of neoplasia (Owen 1986). It is feasible that cartilage cells that 
developed during the reparative phase of fracture healing also become isolated 
within bone may undergo malignant transformation (Bennett and others 1979).
Chronic trauma is another possible explanation for the metaphyseal 
distribution of osteosarcoma (Pool 1990). Evidence for this appears to be:- the 
prevalence in large and giant breeds; the ratio of weight carried between the fore 
and hindlegs is similar to the ratio of tumour development; the low incidence in 
the axial skeleton. This seems to be circumstantial evidence with no objective 
evidence to support it.
The sporadic occurrence of osteosarcoma after fracture is interesting. The 
prevalence following fracture is not known and would be difficult to quantify 
accurately. However, it happens frequently enough to be of concern. Affected 
bones had not necessarily been treated surgically. There are a number of features 
of fracture healing and management that appear to be related to osteosarcoma 
development (Table 8, page 15).
Tumours occurring at fracture sites are unlikely to be sporadic naturally 
occurring tumours as their distribution is different to that of the spontaneous
13
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disease (they are diaphyseal rather than metaphyseal). The lag to clinical disease 
(approximately 5 years) is such that the majority could not have been present at 
the time of fracture (Stevenson 1991).
It is possible that fracture associated sarcomas are related to more than one 
of the potential factors. Obviously release of metal ions cannot be related to all 
instances as sarcomas can develop without internal fixation. Many cell types of 
varying potentials are attracted to fracture sites and conceivably these may become 
trapped within the healing bone. There is often a disturbed pattern of healing 
with instability sometimes associated with infection (Stevenson 1991). Chronic 
inflammation has been implicated in oncogenesis of other tumours -e.g., squamous 
cell carcinoma (McEwan 1989a). The other feature of these areas of bone will 
presumably be an increased population of pleuripotential cells and the various 
substances that stimulate their differentiation.
It is likely that there is more than one pathway to primary bone sarcoma 
development and that the cells that undergo transformation are of similar type and 
degree of differentiation.
BENIGN TUMOURS OF BONE
Benign tumours of the skeleton are rare in dogs (Pool 1990) but a number 
are recognised and these are summarised in Table 12 (page 20). They are of little 
clinical significance, unless they impinge on surrounding tissues, but may be of 
importance in differential diagnosis.
TUMOURS INVADING BONE
Bone may be directly invaded by tumours developing in surrounding tissues. 
These may alter the bony structure and cause bony pathology. A number of such 
tumours are recorded and these are summarised in Table 13 (pages 21-23). These 
tumours may be metastatic as well as being locally aggressive.
Bone may also be the site of metastasis from distant tumours, though this is 
unusual and has a lower incidence in the dog compared to man (Pool 1990). 
However, this may reflect the fact they are often difficult to find and are generally 
not aggressively searched for. Metastases from most types of tumour have been 
recorded with the commonest being carcinomas of the mammary gland, liver, lung 
and prostate (LaRue and Withrow 1989). The bones most affected are the 
humerus, femur and vertebral column It is suggested that the areas that are most 
likely to be affected have high vascularity (Pool 1990).
14
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Factor Possible significance
chronic presence of metal in the body 1. accumulation of metals in remote tissues 
has been identified
2. senitisation of immune system
3. many o f the metals used in implants have 
been demonstrated to be oncogenic in 
experimental animals including chromium, 
cobalt and nickel
4. long term implants (hip prostheses) 
possibly linked to increased rate of 
lymphoreticular disease in man
implant corrosion 1. an implant associated with known 
corrosion problem (Jonas pin) was 
associated with a very high incidence of 
sarcoma formation and osteomyelitis 
(Sinbaldi and others 1982)
2. there are sporadic case reports of 
sarcomas involving bone in dogs (Rosin  
and Rowland 1981) and soft tissues in 
humans related to corroding metallic 
foregn bodies
3. modern implants do not corrode visibly 
but there is a degree of corrosion in the 
region of the screw/ plate interface
altered cellular activity 1. fracture repair involves complex and 
evolving changes in local cellular activity 
with many fairly undifferentiated cell 
types and also the differentiation of cell 
types
2. fracture areas can become areas of 
chronic inflammation if infected or 
unstable
Table 8. Factors that have been identified as having a possible role in post 
fracture sarcoma development (Stevenson 1991).
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Tumour
osteoma
endchondroma
multiple cartilaginous exostoses
bone cyst
fibrous dysplasia
ameloblastoma 
(formally adamantinoma)
Behaviour
slow progressive growth over months to 
years.
no metastasis or malignant 
transform ation reported
benign medullary cartilaginous tumour 
no metastasis or malignant 
transformation reported in animals but 
is recognised in man
developmental disease.
mono- or polystotic cartilage tipped
excrescences protruding from the bone.
growth likely to stop with skeletal
maturity.
malignant transformation likely in 
animals with multiple lesions, 
demonstrated to be hereditary in 
nature (LaRue and Withrow 1989).
rare in d o g s.
cysts are fluid filled and may be 
monostotic or polystotic in distribution, 
aneurysmal bone cysts are very rare in 
the dog(Goldschmidt and Biery 1985).
rare in dogs
characterized by replacement of 
cancellous bone by a fibro-oseous 
matrix (Pool 1990)
rare in the dog
derived from the Rests of Malassez 
(White 1991)_________
Table 12. Benign tumours and similar lesions of bone in the dog.
20
CO
C/3
O
£
O
oPi
&
ID
CD
c  id
u  ■ a  2
i -  3  
3  c r
CD Q  
P  T 3  
^  3« .a 
-2 g >
O  Jxi
•SS Jo
3  
.2
o  . 3
cd 
Xid
CO
3 XT'
CD X I  
i u  2
^  °> >  C/3
cO cO 3 ID
- oid
" OU.
33bo o 
• S2 • £
m cd
• 3  B -
O
c  3  bO .5 
o  - o
3
a j  3  M U G  
3  .c /3  • - «  3 -O ~0
.2 10 X  C/3
CO P
•s o -a
3  
3
6  ^3 IS
3
o  2
■*-' c/3 C/3>-,3 3
&1 u * aID
X
O
aID
X
3
3
(U ID 
X
o o
id-3
- o33
3
O
33t>0 .2
u   [ 1  s  - a  S3
O 3 J-ha, x  w
o
. x
3 c/3
O 8 ID
<±3 _o X
bO O o
B 8
3 *3
3 8
c c/3 ID3
‘bh o c/3
’ ip 3
o 8 '.£PC/3u
3
3
3
- 3
ID
O CDo
a
3
CD
3 *ocH a 3
.2  00 •3 ON
i *±3 O 
u  u
i  I
> >  ^  
0) ID 3  “
cd J  
3
3
.2 -m 3•rs *b
od - 3  
- a
„•> C 32 3
-  ' ?3 <U
X 3  CD
O  3
8  PiID 3
n O *3 J  J2 3  CD w
3 
CD
o—1 . „ 3
3 S
3 2O. 3
3  u  3  cd 3 u,
" O
. 3  1=1k. ■£ 3
3  - S  ->-»0 > 3
1 ^  1 
2 - i P
«  - r  o
C CC3IDo o .2
w
id  
cd 
o
_  3O C/3a,
2  *> -
J J  «  I
IP § Iw 3 J3
3  u
13  J 3
03
8o
- 3bO
3
14--O >^4
O.3b-ID
£
I d_> IDX
m o8
X 2^ GCD■“ IDJ3ooIDO.
X
O OXID i— a3 c d
X O CO
b O a ’ v3
'a 3 u
13
T 3
P i
C
M
i
Cd
0 3
i s
3
2 I13 ~c *303 8  
bO 3
>3
- 3
3  " O  
O  3  
3  8
j |
• 3  5
«  “  a
33 rc. 3
S  2  P
* 3
8
3
3
O
CD 13
-2 e
33
m
3
" O
13
u .
13
r s
’ c/3
3
OCD
13
X
13
0 3
3  - 3  
O  3
-  13 O  D V
3  iP CD OO
o  bn X  oo3  3)2 o\
c/3 3  '  t—I
o noo
c n
- 5  £
■ >  °
> < * -  8  
3  P  " 5
O  X S  • >  
\ S  ! >3 "C w  
i :  D3
§  «  ' 18  u  u
I S  C/3— Its 33 3 c_cy M i)
o  - 3  B
. S P
• 3
:2 B
T 3  O  
B  B S33 -X
8
Oa
6 13p JZcj C3 
•t-i "3.2 3
■ 3  3
^  £  
^  P
3  £
c o  O  
3 r. CO 
CO 3
B &
. £ P
’B
* 3
8
3
_ 3
3
a
3
• 3
8
3
a
3
a
" C
O -i
3  O
3  c0
c/3 83 g
ID CD
J 3
H
• 3
3
3
a
XCD
> o  
, h 00 
O  C 3
S  B
t S  . 2
.2 si_ >
2  BOi • —
• 3  a
^  > >  
h c
s  °
3  -0a  i d
3  - 3
a
- C
CD
3
ID
C/3
3a
O  ID
•£ ■£ 
i  I  -
3  *5 
C 2bO o
o a 
.a a
CD
Q \
0 0
O N
c-HC
c d
G oX) k.
a
ID
a
X
1
T3
" c 0 8•? 3o ID
£
C/3
3
Oi
ID
J 3
3
o  ^  
c  ON 
• -  00 
3  O ' 
O  ^  
2 % a 2
O  - 3  
O  . 3
ID O  
■X ^J  •?
ID 3
X )
I S
>
o
3
21
Chapter 1
Ta
bl
e 
13
. 
Tu
m
or
s 
th
at
 l
oc
all
y 
in
va
de
 
bo
ne
.
TU
M
O
UR
 
TY
PE
 
IN
C
ID
EN
C
E 
AR
EA
 
CO
M
M
O
NL
Y 
BE
H
AV
IO
UR
 
M
A
N
A
G
EM
EN
T 
PR
O
G
N
O
SI
S
A
FF
E
C
T
E
D
43 03
.id' ^'7i Q 
O C7 )c >60 ~
O
Cu —
T3 .S O
03 X O
T3 O —13 is uin a  >
3  & (  360 3 43
- ac
cd
-X
CJ
1)a
cd
CO
5  O 'c/3 00
co >
i3 I
CO l-lBo  { i  
6 £
oocx
oa
6 0o
V-c
a ,
6 0o•a
<u
X
T3
1)
X
6 0
C
"3
>
■>u-
3
' 5
1
- a
8
3
03
CO
E
" 3
03
3
p i
u .
03 1-1O
3
j O n
60 a , OO03 3 O v3
O
t->
3
O iH
£
X 0303
X
3 O
6 0
3
3
&H
M
X
O
X
CO
3
X
E
3 i
Oocx
03
Eo
COCM
O
<o
X
3o cd 
"2 £ 
X . 3  
-  1
O c/3
.2 -o
03 O v
f t  c d  O  <u
03 S2
£ ^<41 -O0 03 
• 5  "cd
S  -S
1  § „1 1  eg> T3
03
X
Mo
- a
3
cd
a,a,
cd
ao
O h
c o
03
>%a.
cdU.
03
X03
-  Bcn  C
</5 o
s& ,  03
03£
co
T3
C
Oa,
s
cd
£
3
X
3  
CX
6
3
Cm3
£  3
13 6 
3 iS o
03 ^  ^
M 1/3
03 m  
-X I 03
X )
"O "o3 
- 3  3  X !  
“ S 3
§  c o  c o
3
6 0"3
03 u  
- 3  c o
33  u - c60 O
C 03 m« 3 * 203 -9 O 033-3 3CO
3
3
CJ
03
3
O
X 3
c o  . O
3 co
M  ^
m -a
03
"cd
cj
O
Chapter 1
.BP•3
-o3
3
>>
3  - 3  
3  i n  
O '  3
CO CJ
3  32 MJ
.bp .203 ~
3  03
£ S
c/3 e
s so *o
03 . 3
13 E 'E 23 co
O "O
* g
03to __ ,
03 ~a  
3  3
S3 *CQ 2
.S 8
E S
03 '—
•7 ?  CO•ft 602 o xa, -a vo
T3 . S  on03 3 >-H
C  3  
03  3  '3 5
- 3  0  0
.E E 06
03 60-a s
E "3
3-a
03
3
03 
03 X3
03 03
3 X X
3 X 3
£ X v .■3
0 O N £ 8
u 00 3u, O N g X3
CO
Oi_
r H
3
03
-03
X 83
X
X
C
CO
0
0 4 ,
OMa.
3
E
. 5
3 CO Cm 3
3 3 O 0
6 0 3
g
03
M |
* 3 O " a S
E
3
X E
X
CO
T3
03
X
60
O
03M
3
O
3 O
2 ^  3  03
60 C  
3  c o
E IE 22
-o
03
3
O
E3
3
3C 03
60 T>^  CO
<3 D
E E
-o
3
3
03 3
c o J ,33 03CJ
03 8
X O
T 3
X
03 CO
X 03 ^ ^
CO T3 r»
• 3
X > ON3 8 1-1
CO
03 03
c o
M
03
M M XO 3
8 M O
o
o-o
X )
3
X
Ta
bl
e 
13 
(c
on
t).
 
Tu
m
or
s 
th
at
 l
oc
al
ly
 
in
va
de
 
bo
ne
.
so
Chapter 1
cn
zr>
O
Z
o
o
a-
3
3cr
o
T3
c d
"O
O
Ot>0
H
z
Ed
£
Ed
O
z
<
cd
o
><
X
Ed
CQ
><
Z
o
o
u
<
Ed
X
Q
Ed
H
U
Ed
Ez*
«<
_>^
2Id
3cr
<o
"O
3
o
s
3 -O« o
3
O
O
O
o
3
U S .> ooo T3
> .523 w 
3
00
"3 £t_> ID 
° 6
S
.2
"d
js
•a
ID
b O
3
Q
>>
3
3X2
O)
C
o
■ f i
VT3
C3
>
C
C3
<D>
JD
•M
OS
PC-wcnU
©
£s
H
e
o
©
i—*
CD
2
cs
H
Ed
V
Z
Ed
Q
U
Z
Edcu
0*
X
O
S
x
H
c/5.3 3
a 23 3
“ 6 
"a3 J20 -5 •3 c
1 8J§ sS
3CD
<D 23
INVESTIGATION OF BONE TUMOURS
Chapter 1
Bone lesions require further investigation for definitive diagnosis. The 
techniques used primarily are radiography and biopsy. Scintigraphy is also 
potentially of value.
RADIOGRAPHY
Currently radiography is the key technique for investigation of 
skeletal disease in the domestic species. Though other techniques (e.g., Computer 
Assisted Tomography-CAT scan, Magnetic Resonance Imaging-MRI) are 
available, their use is restricted by considerations of economics and access.
Plain radiography will reveal changes in bony architecture and soft tissues 
that imply the presence of neoplasia Figure 2 (page 26). These are described in 
Table 14 (page 25). Anatomic position is significant in that classically, though not 
invariably, tumours develop at certain sites (see Figure 1, page 4).
The radiographic features observed are not exclusive to neoplasia as they 
are indicative of bone’s general response to inflammation and erosion. The most 
important differentials in the dog are summarised below:
• osteomyelitis
• response to trauma
• fungal infections (in specific geographic regions)
Classic radiographic appearances for the different sarcomas have been 
described. Current advice is strongly against making a definitive diagnosis based 
on the radiographic appearance alone because the radiographic findings are not 
consistent (Houlton 1984, Thrall and Goldschmidt 1985b). For example in a 
series of 75 appendicular osteosarcomas, reviewed at Bristol Veterinary School, 
only 61% dem onstrated the typical appearance (Gibbs and others 1984). In the 
UK, however, where radiographic findings and clinical situation are appropriate 
the index of suspicion is high. Radiography is also used in the assessment of the 
thorax for pulmonary metastases. Chances of success in recognising early 
metastatic disease are enhanced by:
• radiographing the chest from both lateral aspects
• inspiratory radiographs
The earliest identifiable lesions are approximately 5mm in diameter (Dennis 
1991).
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Bony activity Radiographic change
destructive bony changes loss of trabecular detail, loss of cortical
integrity
productive bony changes periosteal proliferation, production of
new bone, sclerosis
Codman‘s triangle the rapidly growing tum our passes 
through the cortical bone and lifts the 
periosteum. A feature of the 
periosteum's response is calcification. 
This forms a line divergent from the 
cortex (see Figure 2, page 26) 
it is not specific to bone tumours 
(Keally 1987)
soft tissue swelling increase in density and distortion of 
local soft tissue structures
poorly defined margins difficult to define interface between 
normal and abnormal bone
long zone of transition along with poorly demarcated margins 
the amount of bone with an unusual 
appearance is also greater than with 
more benign lesions
Table 14. Radiographic changes observed with primary bone tumours
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Osteosarcoma of the distal femur
NEW BONE  
(PERIOSTEAL RESPONSE
LOSS O F CORTICAJ_ 
DEFINITION
BONE LYSIS / LONG ZONE OF  
TRANSITION WITH 
INDISTINCT MARGIN
CODMAN'S TRIANGLE
Tracing with description of radiographic changes
Figure 2. Radiographic appearance of osteosarcoma.
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Radiographic skeletal survey is advocated by Straw and others (1990) as 
their technique of choice for the detection of skeletal secondaries though, if 
available, scintigraphy is advocated as being the technique of choice by other 
authors (Lamb 1991).
SCINTIGRAPHY
This imaging technique involves the use of radioisotopes to highlight areas 
of the skeleton with increased blood flow and turn over of bone. The isotope used 
in the assessment of the skeleton is 99 mTc diphosphonate. This emits gamma 
radiation as it decays, which is measured with a gamma cam era to produce a 
representation of the selected part of the skeleton. The information obtained can 
be considered as a functional rather than structural interpretation of the skeleton 
(Lamb 1991).
The isotope is distributed in three phases. The first phase is a passive 
distribution to areas of increased vascularity. In the second phase, the isotope is 
distributed to the extracellular fluid. In the third phase, the label is attached to 
the available bone crystal surface. Thus areas of active resorption and new bone 
production will be highlighted. However, many benign lesions also result in 
increased uptake (for example spondylosis deformans, osteomyelitis) and thus this 
technique, though showing the distribution of active areas of the skeleton, does not 
specify their nature. Suspicious regions should be further pursued by biopsy. The 
use of radiography may make the process more selective by eliminating benign 
lesions from those selected for biopsy (Parchman and others 1989).
In man and dogs, this is a very sensitive technique for the evaluation of 
skeletal metastatic disease (Galasko 1987, Lamb 1991). As 50% destruction of 
medullary bone has to occur in man before a lesion will be visualised 
radiographically, the uptake of radioisotope can be useful way of demonstrating 
destruction before it can be detected radiographically (Galasko 1987). 
Scintigraphy has been further refined by the use of radio-labelled monoclonal 
antibodies (Epenetos 1987). These have not, as far as the author is aware, been 
applied to the investigation of the canine disease.
BIOPSY
It is always a worry that biopsy will liberate tumour cells resulting in both 
local and metastatic spread (Robertson and others 1984). However, the risk of 
incorrect diagnosis is greater so that the current recommendation (in man) is for 
biopsy and histological diagnosis (Coombs and Halliday, 1987).
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Obtaining a diagnostic sample is the greatest challenge in biopsy of bone 
tumours. Technically there are a number of problems (see below):
• Lesion may be difficult to visualise without extensive procedure.
• Tumours tend to be heterogeneous.
• G reat variation in tissue density through tumour. This may make loosening 
of a "core" difficult.
• Local inflammatory reaction often intense and difficult to differentiate 
grossly. A false negative may result from biopsy of inappropriate material.
• Danger of pathological fracture with extensive biopsy.
Current practice in veterinary and human surgery is the used of closed 
biopsy, though open biopsy is still advocated by some authors (Smith and Sutton 
1988). Currently, at GUVS, material is obtained with a Jamshidi bone biopsy 
needle (Figure 3, page 29) through a minimal surgical approach. These 
instruments are available in a number of needle gauges and selection depends on 
patient size and lesion position. Currently 8 and 11 gauge needles are in use in 
the Departm ent. In potential resection and grafting patients, the approach is 
directed so that it will be resected during the definitive surgery. This is to reduce 
the likelihood of leaving a trail of neoplastic cells that may compromise the 
definitive surgery if limb sparing is undertaken.
The accuracy of diagnosis from biopsy material varies depending on the 
quantity, quality and area of the sample obtained. Accuracy with the Jamshidi 
needle has been quoted as 91.9% for the diagnosis of the presence of neoplasia 
and 82.3% for the identification of tumour type (Powers and others 1988). This 
compares with a diagnostic accuracy of 93.8% for the Michelle trephine, which 
takes a larger core of tissue, and is associated with a greater risk of fracture of 
smaller bones (Wykes and others 1985). Removed tumours are submitted 
routinely for further evaluation.
There are varying opinions on the best region to biopsy. One study has 
suggested that the radiographic centre results in more diagnostic information 
rather than the transitional zone suggested by others (Wykes and others 1985). 
The taking of multiple samples also might be expected to yield more information 
and is recommended.
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Figure 3. Jamshidi needle
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DEVELOPMENT OF MANAGEMENT REGIMES FOR BONE 
TUMOURS IN THE DOG AND MAN
Osteosarcom a has been suggested by a number of authors as a model for 
the study of the disease in man because of strong similarities in behaviour. These 
similarities have been summarised by Straw and others (1990) and are reproduced 
in Table 15.
Factor Dog Human
incidence in USA 8-10,000/year 1000/year
m ean age (years) 7 14
race or breed large pedigree none
sex distribution male male
body weight > 20kg large individuals
site long bones long bones
stage at presentation 
(Enneking)
stage IIB stage IIB
rate of metastasis 
without chemotherapy
within 1 year within 2 years
sites of metastasis lung > bone >soft tissue lung > bone > soft tissue
effect of chemotherapy improved survival improved survival
Table 15. Summary of comparisons between human and canine osteosarcoma
(Straw and others 1990).
A number of other common features were identified by Misdorp (1980). 
These include evidence that fibrosarcomatous osteosarcomas have a generally 
better prognosis, that tumours appear to occur in stress related areas (if looked at 
across the species) and that in both man and the dog tumours have been associated 
with bone infarcts.
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There are also differences in the clinical picture. In the dog the disease is 
seen in m ature animals whilst in humans it is primarily, but not exclusively, seen in 
adolescents. Thus in the dog it is a disease of the mature skeleton whilst in the 
human it is often observed in skeletons that are still developing. The distribution 
within the skeleton is different, although all sites are thought to be areas of stress. 
In man osteosarcoma may follow on from Paget‘s disease - a disease of bone that is 
not described in the dog.
MANAGEMENT OF OSTEOSARCOMA
Tumours of the skeleton affect its function as their development results in 
destruction of the bony structure and compromise of the soft tissue structures 
along with progressive local discomfort and pain. These local effects are unlikely 
to be fatal unless they lead to local compromise of a vital structure (this is more 
likely in the axial skeleton). It is the disseminated metastatic disease that 
eventually leads to death, usually as the result of euthanasia in the dog.
The classical description of the result of surgical management of 
osteosarcoma of the limb by amputation in the dog was published as a series of 
papers by Brodey (with other authors) over the period 1965 to 19755. A number 
of similar papers have been published that have corroborated these observations 
(Table 16, page 35). Animals managed by amputation alone can be expected to 
live for about 18-25 weeks.
Historically it was recognised that the "classic" surgeons response to a 
neoplasm (i.e. to remove it) had disappointing results when dealing with 
osteosarcomas in humans. In the 1920‘s, 80% of osteosarcoma patients managed 
by amputation died of pulmonary metastasis within a few months (McKenzie 
1987). Until the development of effective techniques to manage the metastatic 
disease, that was how the situation remained. Amputation to relieve discomfort 
was the only meaningful surgical approach. Surgical management could only be 
developed once metastasis could be managed to a reasonable degree.
Surgical management of the primary tumour is a technical challenge if 
anything more than amputation is attempted. In the initial programmes in man, 
the major complications were related to local recurrence and infection (Grimmer 
1987). Experiences with bone allografts have been mixed and currently the use of 
endoprostheses is advocated by many groups. This is further discussed in 
Chapters 4 and 5.
5Brodey 1965, Brodey and Riser 1969, Brodey and Abt 1976
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It is assumed that pulmonary micrometastases are present at initial 
evaluation in the majority of patients (90% of dogs managed by amputation alone 
develop pulmonary metastatic disease within 1 year of surgery). W ithout adjuvant 
chemotherapy 80% of human patients with high grade osteosarcoma develop 
pulmonary metastasis (Westaby 1987). Interestingly, the proportion of people 
surviving 5 years is very similar to that surviving 2 years. This suggests that 
survival is related to the extent of metastatic disease at presentation and its 
control. Individuals with significant metastatic disease or tumours that are 
insensitive to the chemotherapeutic agents will succumb during this initial period. 
An ideal therapeutic regime would eliminate these deposits. Currently the best 
that can be hoped for in both man and the dog is suppression of their development.
Early methodologies were directed at the primary tumour. At the time that 
radiation therapy was evolving as a therapeutic technique, it was applied to 
osteosarcomas as a way of trying to control both the primary and the metastatic 
disease. A variable response was observed and patients with rapidly developing 
tumours often developed metastasis before surgery was undertaken. Interestingly, 
some patients were apparently cured following irradiation of the primary and did 
not require amputation (McKenzie 1987). Further studies in the 50’s and 60’s 
reported further limited success in the control of the primary tumour. There 
seems to be a wide range of response to radiation therapy with occasional tumours 
being very sensitive. This may relate to an apparent subgroup of potentially 
radiosensitive small cell osteosarcomas described above (Table 6, page 9).
Application of radiation to the lung field as a method of controlling 
pulmonary metastasis was subject to randomised trial and showed some increase in 
survival rate at 5 years (McKenzie 1987). Other studies have failed to substantiate 
these observations (Westaby 1987). This work was published at a similar time as 
the reports of chemotherapy that were producing more dramatic results. No 
beneficial effect was observed following pulmonary irradiation in the dog (Owen 
and Bostock 1973).
In contrast, radiation therapy of the primary tumour has been demonstrated 
to be of little value in the canine (Thrall and others 1990). This is probably 
because the small cell osteosarcomas do not occur in dogs. Radiation therapy, 
however, has been demonstrated to have a palliative effect in controlling pain 
though this returns in 4-6 months (McGlennon 1991).
Chemotherapy has been demonstrated to have a positive benefit in the 
management of human osteosarcomas and has greatly improved the prognosis of 
what was previously a hopeless cause. Methotrexate, doxorubicin and cisplatin are 
the currently favoured drugs (Yasko and Lane 1991). Many of the protocols
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involve combination chemotherapy with cisplatin and doxorubicin being popular. 
Extrapolating from this success, similar protocols have been applied to canine 
patients with varying degrees of success (Table 20, page 68-72). However, it has 
been fairly conclusively demonstrated that the use of cisplatin increases the disease 
free interval and life span of selected canine patients. Chemotherapy does not 
prevent or destroy metastatic tumours.
In the management of human patients with pulmonary metastasis, 
metastectomy has been shown to be effective in selected patients (Westaby 1987). 
Resection of solitary pulmonary nodules as a method of controlling limited 
m etastatic disease in the dog is described (Straw and others 1990). The general 
impact on survival in the dog is unknown due to the small number of patients. In 
one group of 22, the median survival time post thoracotomy was 3 months. One 
dog was still alive 36 months following metastectomy.
Immunomodulation using BCG6 has been attempted in the dog (Owen and 
Bostock 1974). BCG stimulates a non-specific infiltration of the lung parenchyma 
with macrophages and "natural killer cells". These are associated with the control 
of neoplastic cells and a local increase in numbers ought to reduce the numbers of 
metastatic cells. Though positive effects were demonstrated in a small number of 
animals there were problems with anaphylaxis and repeated injections are required 
to maintain the effect. Two dogs with apparently early tumours were managed 
using this protocol at Bristol Veterinary School both of which were euthanased 
because of skeletal metastasis within 6 months (Gibbs and others 1984).
Another immunomodulation technique utilising muramyl peptides has been 
described (McEwan 1990). These again are non-specific stimulants of the 
immune system, increasing antibody production and encouraging cellular immunity 
to an antigen. In a double blind trial significant increases in both disease free 
interval and life span were observed. Patients tolerated therapy well.
EVIDENCE THAT NOT ALL OSTEOSARCOMAS HAVE THE SAME 
BEHAVIOUR
A number of features of the biological behaviour of canine osteosarcoma 
suggests that there are biological subsets of the tumour. However, the range of 
behaviour reported does not appear to be as diverse in the dog as it is in man. 
There are rare but consistent reports of animals surviving for long periods with 
known tumours and no evidence of metastasis (Brodey and Abt 1976). Likewise 
there are consistent but infrequent reports of apparent cure by amputation 
(Brodey 1965, Brodey and Abt 1976, Spodnick and others 1991).
6Bacillus Calmette Guerin
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Osteosarcomas in certain areas of the skeleton differ in prognosis. In 
particular, those of the skull have a comparatively long interval to metastasis whilst 
those of the hind limb have been associated with aggressive behaviour by one 
author (Misdorp 1980) whereas contrary observations have been reported by 
another (Brodey 1965). Amongst tumours treated with chemotherapy, there is a 
noticeable variation in the response with occasional instances in which there are 
strikingly long periods of remission. Radiographically atypical lesions have been 
associated with apparently different behaviour (Gibbs and others 1984).
SUMMARY
Osteosarcomas are relatively uncommon tumours in the dog (though the 
incidence is much higher than in the other domestic species and man). They are 
of uncertain aetiology though there a number of well-recognised risk factors. 
O ther sarcomas of the skeleton of the dog are rare (in contrast to man but in 
keeping with the other domestic species). Benign bone tumours are very rare in 
dogs.
The cell lineage of the varies sarcomas of bone is unknown. In the dog 
they are primarily osteosarcomas However, at what point along the 
differentiation pathway does transformation occur ? W hether the various 
sarcomas are of the same origin or represent neoplastic transformation of different 
lineages is uncertain.. It is likely, however, that the transformed cell type is 
associated fairly specifically, at some stage, with osseous tissue as extraskeletal 
bone and cartilage tumours are exceedingly rare in both man and the dog (Patanik
1990). Some pointers to the origin of the affected cell types comes perhaps from 
the analysis of sarcomas that occur following fractures. Primitive cell types related 
to bony development, perhaps trapped in the bony structure, undergoing malignant 
transform ation are a possible origin. This may also be relevant to the metaphyseal 
distribution.
The commonest site of osteosarcoma development is the appendicular 
skeleton. Tumours of the axial skeleton show a much higher incidence of 
chondrosarcoma, which is generally less aggressive. The osteosarcomas that 
develop in this region are also reputed to have lower rates of metastasis.
It is known that the flat bones and the long bones have essentially different 
patterns of development. It could be speculated that the type of bone influences 
the type of sarcoma that are likely to develop. It is also possible that the type of 
bone and anatomical region in which a sarcoma develops influence its behaviour.
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Chapter 1
Prognosis is thought by some authors to vary between the various classes of 
osteosarcoma identified. This seems to be a subjective opinion in that their low 
incidence makes this difficult to demonstrate statistically. The more fibrous 
tumours are thought to have the best prognosis, in a similar fashion to man 
(Misdorp 1980), whilst the telangiectatic ones are thought to have the bleakest 
outcome, again similar to man (Gleiser and others 1981).
Osteosarcomas are classified into histological groups, though this does not 
reflect their potential behaviour. A number of staging systems are in use in the 
human field but none yet has been widely accepted in veterinary work. This is of 
particular relevance when comparisons of the results of therapy are made not only 
within groups of reported animals but also between centres under taking similar 
and differing modes of management. It would be useful if a staging system was 
adopted as standard to facilitate the assessment of the m anagement regimes.
Amputation is thought of as being palliative with respect to the 
development of metastatic disease in both man and the dog. However, there is 
probably an increase in lifespan of selected patients as amputation gives excellent 
control of associated pain and hence is likely to delay the time to euthanasia 
(euthanasia due to chronic pain being likely to occur before that due to clinically 
significant metastatic disease).
Though the results of chemotherapeutic management of the disease in the 
dog have perhaps not been as encouraging as in man, there have been significant 
improvements in life expectancy associated with the use of cisplatin, in conjunction 
with both amputation and limb salvage procedures.
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PLATINUM CONTAINING ANTI-NEOPLASTIC 
AGENTS:
DISCOVERY AND OVERVIEW OF USE IN HUMAN 
ONCOLOGICAL PRACTICE
Chapter 2
DISCOVERY AND DEVELOPMENT OF CISPLATIN
The initial observation that led to the development of cisplatin was made 
during a series of experiments to assess the growth characteristics of Escherichia 
coli in electromagnetic fields (Rosenberg and others 1965). The use of platinum 
electrodes inhibited cell division and the bacteria developed as long, filamentous 
forms. This was demonstrated to be due to the production of electrolysis 
products, formed because of the presence of ammonium chloride in the growth 
medium. These were principally cw-diamminetetrachloroplatinum (IV) and 
cfs-diamminedichloroplatinum (II).
The development of these filamentous forms of the bacteria implied, in the 
presence of otherwise unaffected cell functions, interference with DNA replication. 
A similar effect is observed with other DNA affecting agents such as ultraviolet 
light, high energy radiation and alkylating agents (Pinto and Lippard 1985).
This observation was pursued and a group of platinum containing 
complexes that inhibited cell activities was isolated. The more ionised complexes 
tended to be bactericidal whilst the neutral ones had an inhibitory effect on 
division. The stereo-chemistry of the complexes was demonstrated to be 
significant with the complementary trans form, though having some bactericidal 
activity, having no effect on cell division (Pinto and Lippard 1985).
The intuitive step was to test these compounds against established mouse 
tum our models (Rosenberg 1985). Success in the animal model led to clinical 
trials on terminal human patients, with encouraging results. As a result of these 
observations and many other experiments, cisplatin was licensed for clinical trials 
in 1972, with full Federal Drug Authority approval following in 1979. It is now a 
major part of the armamentarium in human oncological chemotherapy (Pinto and 
Lippard 1985).
USE IN THE HUMAN PATIENT
Cisplatin has been assessed against many human malignancies and has 
found its most frequent applications in the management of soft tissue neoplasia 
(below).
testicular
metastatic ovarian
cervical
lung
bladder
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It has also used in the management of osteosarcoma in combination with 
doxorubicin.
In human oncology cisplatin is of major importance as a chemotherapeutic 
agent. It has had a marked impact, in combination with vinblastine and 
bleomycin, on the management of testicular tumours, a major cause of non- 
traum atic mortality in young men, in which the cure rate is now approximately 
70% (Loehrer and others 1991). The drug also is of importance in the 
m anagem ent of ovarian tumours and inoperable solid sarcomas.
The development of chemotherapy regimes in general has had an impact on 
survival times for patients with osteosarcoma. Long term  survival (greater than 5 
years) has been reported to be 50-76% (Yasko and Lane 1991).
Initial clinical application of cisplatin in humans quickly confirmed the 
renal toxicity that had been observed in experimental animals (Rosenberg 1985). 
In addition, other toxic effects became apparent. Toxic effects are correlated with 
both the magnitude of plasma levels achieved during infusion and with duration of 
exposure to the drug. There are a number of clinically important toxic effects 
induced by cisplatin in human patients (Table 17).
TOXICITY
Toxic effect Mechanism
renal tubular necrosis major damage in the distal part of the proximal 
tubule (cf the dog, page 50) 
particularly magnesium due to interference 
with uptake
depression of myeloid and platelet series 
damage to primary sensory neurones in the 
spinal ganglia (Cavaletti and others 1991) 
overdose may produce acute central nervous 
toxicity (Fassoulaki and others 1989) 
damage to the rapidly dividing cells of the 
gastrointestinal mucosa 
centrally mediated
can be severe enough to prevent patients 
returning for further cycles of their treatment 
damage to the outer hair cells of the cochlea 
(Gandara and others 1991)
electrolyte wasting
bone marrow suppression
peripheral neuropathies including loss of high
level acuity in hearing
acute gastrointestinal toxicity
nausea and vomiting associated with infusion
ototoxicity
Table 17 . Toxic effects of cisplatin in man.
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The renal toxicity of cisplatin is broadly proportional to the dose given. 
Assessment of renal function is important and the dose administered may be 
altered depending on an individuals renal function. In a group of patients 
undergoing multiple cycles of cisplatin, those ultimately developing renal toxicity 
exhibited significantly higher levels of plasma platinum during the infusion 
(Campbell and others 1983). Interestingly, in these patients pre-treatment 
creatinine levels did not correlate with renal toxicity (however, a more useful 
param eter would have been measurement of renal function - see below).
The development of peripheral neuropathy is a feature of repeated cycles of 
the drug (G andara and others 1989). The administration protocol has been 
implicated in the development of neuropathies in man and experimental follow up 
in a rat model has shown differences in platinum concentration in nervous tissue 
depending on protocol but with the same total dose (Cavaletti and others 1991).
Cisplatin affects the stem cells related to the production of granulocytes and 
platelets. The factors that influence the renal toxicity are not well correlated with 
the development of myelosuppression.
RENAL TOXICITY
The cellular mechanism of cisplatin toxicity is unknown (Daugaard and 
Abidgaard 1989). There are problems interpreting the pathophysiology of the 
renal insult because it appears to differ between species. There is also variation in 
the response between different areas of the kidney. A heavy metal type of 
toxicosis related to activation of the renin-angiotensin system was thought to be a 
component of the toxic effect (Shapiro 1989), though this is not now thought to be 
the case (Daugaard and Abidgaard 1989).
The major region of renal insult is the proximal convoluted tubule 
(Daugaard and Abidgaard 1989). Cisplatin toxicity is initiated by an acute tubular 
impairment followed by changes in renal blood flow. At 48-72 hours post 
administration there is impairment of both proximal and distal tubular function 
and an increase in vascular resistance (Daugaard and Abidgaard 1989). The 
nephrotoxic action is thought to be related to the main aquation product of 
cisplatin (Daugaard and Abidgaard 1989). This may be one of the reasons 
carboplatin (another platinum containing chemotherapeutic) is less nephrotoxic 
(Daley-Yates 1985).
Param eters such as plasma creatinine and urea are not good indicators of 
renal function. They are only become altered in uncompensated renal disease and 
as such are of little use in detecting subtle effects on renal function. They are also 
affected by the state of other body systems (e.g., liver dysfunction will affect urea 
production; cachexia will affect creatinine release).
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Previously, the preferred method of assessing glomerular filtration rate was 
endogenous creatinine clearance as it is relatively non-invasive. However, 
because of problems with the technique it has now been replaced by 51Cr-EDTA 
clearance (Daugaard and Abildgaard 1989).
AMELIORATION OF TOXICITY
It was quickly discovered that toxic side effects could be ameliorated by 
influencing renal function and manipulating the time over which the drug was 
given (Rosenberg 1985). It is now routine clinical practice to administer cisplatin 
in association with pre-infusion fluid loading and diuretics.
The action of the diuretics that is related to renal protection is uncertain 
(Safirstein and others 1985, Daugaard and Abildgaard 1989). However, it is 
thought that the partial renal protection offered by these drugs in humans is not 
attributable to changes in urinary excretion, plasma clearance or reduced levels of 
platinum (Daugaard and Abildgaard 1989). The use of frusemide has not been 
shown to have a positive benefit in humans and is not recommended (Daugaard 
and Abildgaard 1989).
It is known that in the initial phase platinum is excreted rapidly by the 
kidneys. This is obviously increased by diuresis but this does not seem to 
adversely affect the therapeutic effect (Hayes and others 1977). It has also been 
demonstrated that giving the drug as a prolonged infusion decreases toxic effects 
without reducing therapeutic efficacy (Hayes and others 1977).
The use of hypertonic saline has been demonstrated to have a protective 
effect on the kidneys. Studies on platinum in the plasma ultrafiltrate suggest that 
a protocol involving saline pre-hydration and a hypertonic saline vehicle for the 
cisplatin encourage the uptake of the drug by the tissues of the body (Dumas and 
others 1990). The use of this combination resulted in significant decreases in the 
maximal plasma free platinum concentration, the degree of protein binding after 
infusion and reduced urinary excretion.
Toxicity is also a function of the time of day the drug is administered. 
These effects have been observed in humans (Hecquet and others 1985), dogs and 
rats (Hardie and others 1991). This relationship to the circadian rhythm may be 
related partly to the diurnal variation in plasma proteins but it must be 
remembered that renal function increases at a similar period (Hecquet and others 
1985). Diuresis has been shown to be most effective at protecting rats when 
applied during the most favourable period of the circadian cycle.
Though the development of less toxic platinum containing drugs is one 
method to approach the side effects, these have so far also had significant toxic 
effects. The concepts of protection and rescue are well recognised in
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chemotherapy and are used routinely with some drugs (e.g., methotrexate and folic 
acid). The use of saline diuresis and mannitol diuresis have been shown to protect 
against nephrotoxicity. A number of drugs have been developed that protect cells 
from the effects of cisplatin.
WR-2721 is an organic thiosulphate that, after biotransformation, enters 
cells and chelates cisplatin metabolites, inactivating them. Differences in pH  and 
alkaline phosphatase between normal and malignant tissues result in a higher 
uptake in normal cells. Clinical trials demonstrated protection against nephro-, 
oto-, neuro- and myelo- toxicosis whilst antitumour activity was maintained 
(G andara and others 1991).
Diethyldithiocarbamate (DDTC) is a chelating compound with an 
established clinical use for nickel and cadmium poisoning. The protective effect is 
by chelation and removal of tissue bound platinum. The DNA adducts that are 
responsible for cisplatins antitumour effect are not affected. Protection against 
nephro-, gastro- and myelo- suppression have been demonstrated in animal 
models. DDTC is unique in that of all the proposed protecting agents it can be 
given effectively both before and after cisplatin therapy (G andara and others 
1991).
A number of potentially useful drugs are under evaluation. It can be seen 
that any single drug does not protect against all the potential toxic effects of 
cisplatin. For example thiosulphate, though protecting against nephrotoxicity, 
does not protect against gastro- and myelotoxicity in the way that DDTC does 
(Leeuwenkamp and others 1990).
Myelosuppression can be ameliorated by the use of recombinant 
granulocyte colony stimulating factor (Saito and others 1990).
ADMINISTRATION
There are a number of administration protocols described for cisplatin in 
human oncology. Authors state that the ideal technique has yet to be described. 
Doses can be very high with protocols involving doses of 180-220 mg n r2 described. 
The standard dose is in the region of 50-70 mg n r2 every 3-4 weeks (G andara and 
others 1989).
Cisplatin is administered intravenously, intra-arterially and intraperitoneally 
depending on tumour type and location. In the therapy of osteosarcoma where 
limb salvage is envisaged, it is popular to give an intra-arterial infusion. This has 
led to an increase in the number of limb salvage procedures, as it reduces the bulk 
of the tumour. To date, there has been no demonstrable benefit to long term 
survival using this technique as opposed to intravenous therapy (Yasko and Lane
1991).
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PHARMACOKINETICS
The parent drug has a short T y 2 in the plasma of about 30 minutes, with 
40% of the dose appearing in the urine within 2 hours (Reece and others 1987). 
The decay of platinum in the plasma ultrafiltrate has been reported by a number of 
authors and is presented in Table 18. It is described as being uni- or bi­
exponential and is fairly rapid. It is thought that after 4 hours the platinum in the 
plasma ultrafiltrate represents metabolites and products of aquation of uncertain 
cytotoxicity (Reece and others 1987).
Author Dose 
(mg nr2)
Duration of 
infusion 
(minutes)
ti/2 a  
(minutes)
*1/20
(minutes)
Exponentials
Gullo and others 50 60 22 1
(1980)
Belliveau and 125 7200 178 1
o th e rs (1976) 120 30 39
Reece and 80 120 35.6 1
o th e rs (1987) 100 27.4
120 29.0
Erlichman and 50 15 1.7 46.2 2
o th e rs (1987)1
Dumas and 100 20 22.8 1
others (1990)
Saito and others 25 4200 not stated 126 2
(1990)
Table 18. Decay of platinum in plasma ultrafiltrate in human studies, following
infusion.
The area under the concentration-time curve (AUC) for platinum in plasma 
ultrafiltrate given as a 5 day continuous infusion of 125mg n r2 (in total) was 0.16 ng 
min b1 (Belliveau and others 1976) and 0.15 ng min W (Saito and others 1990). A 
thirty minute infusion of 120 mg n r2 had an AUC of 0.08 ng min H (Belliveau and 
others 1976). Urinary excretion is reduced by prolonged infusions, suggesting 
increased retention by body tissues.
lrThe original paper is confusing on this data and this is the author‘s interpretation.
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OTHER PLATINUM CONTAINING CHEMOTHERAPEUTICS
The development of cisplatin quickly established that renal toxicity was a 
significant dose limiting factor. This stimulated the search for other platinum 
containing compounds with less toxicity.
An analogue of cisplatin - carboplatin (diammine 1,1-
cyclobutanedicarboxylate platinum II) is currently licensed for use in man
(Paraplatin, Bristol-Meyers Pharmaceuticals2). Like cisplatin, carboplatin 
undergoes activation by aquation. It is known that one of the metabolites of 
carboplatin is cisplatin (Daley-Yates 1985).
Carboplatin does not exhibit the dose limiting renal toxicity of cisplatin. 
This obviates the need for the complex hydration protocols. It does, however, 
have significant toxic effects on the bone marrow that produce dose limiting effects 
(Calvert and others 1989) and has also been shown to be ototoxic, though clinically 
significant deafness does not occur under normal usage (Kennedy and others 
1990). These effects are given as a reason that carboplatin is unlikely to replace 
cisplatin in routine clinical work (G andara and others 1991).
Carboplatin is currently recommended for ovarian carcinoma and small cell 
carcinoma of the lung. Clinically it has similar anti-tumour activity to cisplatin but 
has enhanced activity against human small cell carcinomas of the lung. Not all 
tum our lines show cross resistance with cisplatin (Daley-Yates 1985). These
observations suggest some difference in mechanism.
OTHER ANALOGUES UNDER DEVELOPMENT
The success of platinum containing drugs in chemotherapy has provided the 
commercial stimulus for the further investigation of analogues of cisplatin to find 
the ideal drug with high efficacy and low toxicity. Carboplatin is licensed and 
iproplatin and (glycolate-0,0‘) diammineplatinum (II) are under evaluation 
(Fukuda and others 1990).
Another group of compounds selected for further investigation are organic 
dye - platinum complexes. These are hoped to have the membrane permeability 
of the dye component and the cytotoxicity of the platinum containing drugs (Page, 
personal communication3).
2Bristol-Meyers Pharmaceuticals, Uxbridge, UB10 8NS
3Dr. R. Page, College of Veterinary Medicine, North Carolina State University, Raleigh, North 
Carolina, 27606.
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SUMMARY
Cisplatin is the first of a family of platinum containing chemotherapeutic 
agents. The discovery of this group is an interesting example of serendipity, 
though the application of Rosenberg’s observations to models of cancer was an 
intuitive step.
Though cisplatin has revolutionised the therapy of certain sarcomas in man 
it is not without significant morbidity from associated side effects. As the response 
is dose dependant, these limit the potential anti-tumour activity. Hence the 
am ount of effort devoted to improving efficacy whilst reducing side effects and the 
search for new less toxic analogues. Though nephrotoxicity was the first significant 
problem  to be encountered, this is now well managed and the most important 
dose-limiting toxicity is in the form of peripheral neuropathies which can confine 
patients to a wheelchair (Gandara and others 1991). Along with the development 
of new platinum drugs goes the search for protective drugs that can be 
adm inistered in conjunction with cisplatin to reduce its side effects.
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PHARMACOLOGY OF CISPLATIN IN THE DOG
USE OF CISPLATIN IN THE CANINE PATIENT
Chapter 3
Though cisplatin was licensed for use in humans in 1979 and dogs had been 
a major experimental animal during the initial pharmacological evaluation, the 
first reports of its therapeutic use in animals only appeared in the mid 1980‘s 
(M elhaff and others 1984, Page and others 1985). The first publications were 
anecdotal reports of the drug’s use in a number of clinical situations (Table 20, 
pages 68-72). Initial experience demonstrated some beneficial effect rather than 
the spectacular results that were so exciting in some of the human tumours. 
However, sufficient effect was observed to encourage further investigation and to 
focus on the protocol for administration that should be adopted.
Initially little clinical work was performed due to the prohibitive cost of the 
drug and the technical problems associated with its administration (Page and 
others 1985). Many of the later papers acknowledge the gift of the drug by the 
manufacturers. Currently in the USA, clinical use is declining because of the less 
readily available supply of "free" drug and client resistance to the full economic 
cost (R. Page, personal communication1). One of the biggest institutions reporting 
on the clinical use of the drug (Colorado State University) is readily given 
osteosarcoma referrals from other veterinary institutions because of their current 
ability to defray costs of therapy due a number of funded projects. The cost of 
drugs for these patients was not passed on to owners.
PHARMACOKINETICS
Most of the work on the fate of cisplatin in the dog has looked at total 
plasma platinum and tissue distribution. Some aspects of the fate of platinum in 
the plasma ultrafiltrate are described (Riviere and others 1990, Hardie and others 
1991). It was appreciated in the early experiments that there was a biphasic decay 
of plasma platinum with a rapid early phase (t1/2a  of < 1 hour ) and a prolonged 
terminal half life (t1/2 (3 of 4-5 days). Platinum was still detectable in plasma 12 
days after administration (even by relatively insensitive analysis). Within 4 hours 
50-60% of the administered platinum is excreted in the urine (Litterst and others 
1976).
After intravenous administration, the retention by different organs is not 
uniform. The greatest concentrations are seen in the kidneys. The 
parenchymatous organs such as liver, uterus and lung have similar concentrations, 
about 30% of that seen in the kidney tissue (Litterst and others 1976). The
iDr. R. Page, College of Veterinary Medicine, North Carolina State University, Raleigh, North 
Carolina, 27606.
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relative distributions are not altered by the dose administered but can be altered 
by whole body hyperthermia (Reviere and others 1990).
Cisplatin is an inorganic co-ordination complex with four ligands. These 
ligands are the reactive parts of the complex and the drug’s activity relates to their 
substitution, which depends on the environment in which the compound is present. 
The two chloride groups are the most reactive and undergo hydroxylation in an 
aqueous environment. The rate of this reaction is related to the chloride 
concentration. In the high chloride environment of the extracellular fluids of the 
body (103mM) this equilibrium does not proceed to any extent (Daley-Yates 
1985). In the low chloride cellular environment (3-4mM) the production of the 
highly reactive substituted species is encouraged (Lim and Martin 1976, quoted by 
Daley-Yates 1985). A number of platinum species are produced, the distribution 
being related to properties of the environment. It has been estimated that in the 
plasm a of mammals the various hydrolysed species represent about 2% of the total 
platinum  (Lim and Martin 1976 quoted by Daley-Yates 1985) whilst in the 
intracellular environment it is approximately 42% (Lim and Martin 1976 quoted by 
Pinto and Lippard 1985).
a . _____ 7 NH3
Cl NH3
NH3 \
+ CI-
H20 +NH3
NH3 NH3
H20 +NH3 NH3H20 +
+ CI-H20 +NH3 NH3
P l a s m a  [ C l - ]  =  1 0 3 m M  C e l l  [ C 1 - ]  =  4 m M
Figure 4. Aquation of cisplatin2. 
WHAT IS IT IN THE CIRCULATION THAT IS RESPONSIBLE FOR THE 
ACTIVITY
Cisplatin is an unreactive compound that undergoes passive activation 
(aquation) by hydrolysis of the chloride ligands (Siddik and others 1985). The
2Adapted from Gandara and others 1989
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parent drug enters the cell by passive diffusion (Rosenberg 1985). The active 
form(s) are a product of aquation. There may be a number of platinum species 
generated that are related to the clinical action. Daley-Yates (1985) suggest that 
the nephrotoxicity of cisplatin is related to the amount of its primary toxic 
m etabolite that develops in the plasma.
CELLULAR ACTIVITY
Cisplatin induces its cytotoxic effect by binding to DNA. Replication is 
halted but the continued growth observed in vitro suggests that RNA and protein 
synthesis are essentially unaffected (Pinto and Lippard 1985). The effect is on 
DNA as template rather than on the enzymatic processes that are involved in DNA 
synthesis. The failure of the DNA template is related to the inter- and intrastrand 
cross linkages that form between the cisplatin and DNA. It is likely that the 
interstrand cross linkages are of limited importance in the biological activity of 
cisplatin, with most importance being attached to the intrastrand linkages (Pinto 
and Lippard 1985). There are also linkages formed between cell proteins and 
DNA though the significance is uncertain. Cisplatin affects cells during all phases 
of the cell cycle but the effect is realised during cell division (Shapiro 1989).
There is evidence that one mechanism of cisplatin resistance is related to 
the cellular DNA repair processes. Cell lines with known deficiency in this 
process are more susceptible to the cytotoxic effects of cisplatin (Pinto and Lippard 
1985).
THE REASONS FOR ASSESSING UNBOUND PLATINUM IN THE PLASMA
Cisplatin is almost irreversibly bound to plasma proteins, in particular 
albumin (Briand and others 1986). Some protein-bound platinum will react with 
strong nucleophiles, though this is probably only of relevance in rescue procedures 
that utilise such compounds (Hegedus and others 1987). It also binds to other 
constituents of plasma, not all of which are identified. Though there is some 
binding to cells in the circulation, this is a small proportion (see page 58). There 
is also irreversible binding to tissue proteins. Though some of this may be 
released at low levels over prolonged periods, the amounts involved are unknown 
and interest is in the relation to toxicity rather than clinical effect (Matheson and 
others 1989). Platinum will also be released by the turnover of plasma proteins 
(King and others 1986).
It is thought that the pharmacologically active fraction of the drug is that 
which is unbound in the plasma (Hardie and others 1991). This is usually assessed 
by measuring platinum levels in plasma ultrafiltrate. However, as the molecular
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weights of all plasma constituents to which the drug binds is not known, there is no 
consensus on what size of filter to use. Riviere and others (1990) demonstrated no 
difference in apparently unbound platinum when using a variety of filter sizes (10- 
30,000 Daltons). It must be remembered that the platinum concentration does not 
represent levels of cisplatin per se but will include its aquation products as well 
(Reece and others 1987).
TOXICITY
Most of the toxic effects seen in man are encountered in the dog with the 
exception of the peripheral neuropathies and ototoxicity (transient incidence of 
LMN disease reported in one dog, Melhalff and others 1984). In man these are 
problems of repeated cycles of the drug, which are not routinely utilised in the dog. 
A single case of myasthenia has been reported associated with cisplatin 
chemotherapy (see page 11) (Moore and others 1990). One instance of grand mal 
seizures and sudden death 3 hours after administration has been observed (Knapp 
and others 1988). The major side effects observed in the clinical application of 
the drug in the dog are summarised in Table 19 (pages 52-57). Experience with 
cisplatin has shown it to be of tolerable toxicity in the dog if carefully administered 
and the patients monitored. Close monitoring does reveal some sub-clinical toxic 
effects.
Renal toxicity has not been a major clinical problem though in those studies 
where it was most meaningfully assessed (using creatinine clearance) there was 
evidence of progressive depression in renal function in some individuals (Shapiro 
and others 1988a, Shapiro and others 1988b). Sporadic instances of individual 
animals developing azotaemia occur throughout the literature. However, the 
design of administration protocols has led to amelioration of the clinical problem.
The major area within the kidney affected by cisplatin is the s3 segment of 
the proximal convoluted tubule (Daugaard and Abildgaard 1989). The immediate 
effect of cisplatin administration in the dog is a decrease in the fractional and 
absolute proximal resorption rates of sodium and water. This occurs despite the 
renal blood flow and glomerular filtration rate remaining unchanged during the 
initial period. In the 48-72 hour period there is a dysfunction in the distal tubule 
resorption capabilities and a rise in vascular resistance. There is polyuria as a 
result of impairment of the renal concentration mechanism (Daugaard and 
Abildgaard 1989). Some of the renal toxicity was previously attributed to a heavy 
metal influence on the renin-angiotensin system (Shapiro 1989) but this is now 
thought to be unlikely (Daugaard and Abildgaard 1989). The cellular mechanism 
of renal toxicity is unknown (Daugaard and Abildgaard 1989).
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The toxicity of cisplatin is time dependant in several species. There is 
significantly greater toxicity in the afternoon as compared to the morning. This is 
related to significant changes in the pharmacokinetics of drug. Afternoon 
administration is associated with significant decrease in the mean residence time of 
the platinum in the plasma ultrafiltrate and a significant increase in urinary 
excretion of platinum. There was a trend for an increase in clearance coupled 
with a decrease in the area under the time concentration curve and volume of 
distribution at a steady state but these were not significant (Hardie and others 
1991).
In more recent clinical reports, myelosuppression has been the most 
prevalent toxic effect. The dog model used in experiments to confirm the 
usefulness of mannitol diuresis in protecting against renal toxicity showed no 
protection from myelosuppression (Cvitkovic and others 1977).
Vomiting after therapy has been described by many authors though in no 
instance has it been cited to be dose limiting. The associated nausea that is so 
well recognised in humans is impossible to assess objectively in the canine patient 
and may be underestimated. Most protocols make some attem pt to ameliorate 
this potential side effect using drugs such as metoclopramide and chlorpromazine. 
In a retrospective study of 115 cases, the total dose of cisplatin was identified as the 
most significant factor in the incidence of emesis (Ogilvie and others 1989a). It 
was significantly more prevalent in smaller dogs, which may be related to the 
proportionally higher doses these animals received (doses are based on surface 
area) and possibly poor assumptions used in the construction of the tables for 
calculating surface area from body weight. Disappointingly, pretreatm ent with 
anti-emetics did not reduce the incidence of vomiting.
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ASSESSMENT OF PLATINUM
Chapter 3
One of the aims of this project was to assess certain of the pharmacokinetic 
param eters of cisplatin in some of the patients managed with cisplatin 
chemotheapy at GUVS. This involved taking blood samples before, during and 
after drug infusion. These were analysed for their content of elemental platinum.
OBTAINING PLATINUM SAMPLES FROM PLASMA ULTRAFILTRATE:
The plasma samples were prepared from venous blood samples taken from 
a catheter placed in a peripheral vein before the beginning of the infusion. These 
were rem ote to the catheter utilised for the infusion of the chemotherapeutic and 
the administration of the other drugs used in the protocol.
On withdrawal the samples were stored in lithium heparin tubes (Starstent) 
to allow the preparation of plasma samples. These were held at room 
tem perature until such a time as the plasma could be obtained and the samples 
centrifuged. This was normally within 2 hours and usually significantly shorter.
The platinum species were obtained using the Amicon Centrifree 
m icropartition system3. This system is based around a micropore membrane that 
retains molecules > 25,000-30,000 Daltons (Amicon Ltd, personal communication) 
and effectively removes the proteins found in plasma (>99.9%, Amicon Ltd). 
Thus plasma bound drug is retained and the filtrate contains the unbound ligand. 
This technique was selected as it is technically straightforward and requires little 
laboratory time.
Though a variable volume of filtrate is produced it has been demonstrated 
that the concentration of solutes in this this is representative of their concentration 
in the protein free portion of the plasma sample (Amicon 1989). One millilitre 
aliquots of blood were taken from the lithium heparin tubes after agitation and 
centrifuged for 3 minutes at 15,000rpm in disposable polyethylene tubes. The 
system (see Figure 5) was charged with 500gl plasma and centrifuged at 3500 
(approximately equivalent to 1000 xg) for 25 minutes at 5°C. It was observed that 
a num ber of the samples were haemolysed. This was considered as a possible 
source of confusion in the analysis of the platinum levels. However, it is unlikely 
that haemolysis would contribute significantly to free platinum levels (except if 
bound to molecules of <25,000 Daltons) as little is present within the erythrocytes 
(Litterst and others 1976b) and that which is associated with these cells is likely to 
be irreversibly bound to components of the cell contents (McCanish and others 
1981). Platinum bound to molecules of less than 25,000 Daltons would pass
3Am icon Ltd., UpperMill, Stonehouse, Gloucestershire, GL 102JB. (045-382-5181)
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through the filter during centrifugation, however, these quantities are likely to have 
been small. This may be of relevance where only low levels of unbound platinum 
are present.
The protein free extract collected in the polyethylene cup, the top portion 
of the system was discarded and the cap applied. The specimens were stored at 
-20°C until analysed.
A num ber of samples were mistakenly stored by the SURRC for a 
prolonged period at room temperature. This resulted in the loss of water, and as a 
result, though the platinum could be detected the actual concentration that was
aRESERVOIR  -----'
CAP------------------ ►
fO l
SAMPLE
RESERVOIR
MEMBRANE
SUPPORT
BASE
O-RING
YMT
MEMBRANE
FILTRATE
CAP
FILTRATE
CUP--------
Figure 5. The component parts of the Amicon 
Centrifree system4
represented could not be calculated. As a result a considerable number of data 
points were lost, affecting final analysis of the infusions.
4U sed with permission
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METHODS AVAILABLE FOR PLATINUM ESTIMATION IN BIOLOGICAL 
SAMPLES
The method of estimating platinum concentration in tissues and body fluids 
has primarily been by variations of atomic absorption spectrophotometry. Litterst 
and others (1976) suggested a sensitivity of lOng/ml (with estimates down to 3- 
4ng/ml). A recent assessment by Tothill and others (1990) for a graphite furnace 
atomic absorption spectrometer gave a the same limit of detection.
Currently the most sensitive system routinely used is the inductively coupled 
plasma mass spectrometer (ICP-MS). This is quoted to have a limit of detection 
of O.lpgh1 (equivalent to + /-  O.lppb5) of platinum (Delves 1985, Tothill and others
1990). This is about a one hundred fold increase in sensitivity over atomic 
absorption spectrophotometery. The calculated accuracy for the samples 
submitted from the patients included in this thesis was + /-  0.2 ppb (or O^ngml-1)6.
High performance liquid chromatography has been described having a 
sensitivity of 2.5ng/ml (Reece and others 1987). A recent suggestion for an 
equally accurate but cheaper method was made by Nygren and others (1990) using 
adsorptive voltammetry. This also has the advantage of avoiding the small degree 
of matrix effect that is found with the ICP-MS technology.
Problems occur in the determination of low levels of elements due to the 
matrix effect. This can be increased by the nitric acid used for tissue digests. This 
is greater for atomic absorption spectroscopy than it is for ICP-MS (Tothill and 
others 1990) and is the major factor for its lower resolution. Cross over may occur 
if samples with high concentrations are analysed proceeding ones with lower levels. 
Planning of the order of sample analysis, attention to cleaning and the use of 
internal standards are used to minimise these effects.
The major disadvantages with ICP-MS technology are the capital and 
running costs, which are substantial (the argon carrier gas is an expensive 
consumable).
OUTLINE OF THE TECHNOLOGY
The material to be analysed is presented in solution (this is made up in 
hydrochloric acid). The first procedure involves a nebuliser, the products of which 
are exposed to a high temperature inductively coupled plasma. This produces 
positively charged ions. These pass into a high vacuum quadrapole mass 
spectrometer which carries out multi-element analysis. Effectively the ions in the
5ppb = parts per billion
6M s T. Shimmied, SURRC, East Kilbride
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plasma stream are separated according to the degree of deflection by the magnets. 
This is related to their atomic mass.
Specificity is high and interference from other elements is low especially at 
high atomic weights. This makes the technique ideal for the analysis of platinum 
(Tothill and others 1990). As the technique is very sensitive small samples can be 
managed.
The instrument used for these analyses was a VG Plamsaquad PQ1 fitted 
with a Fassel-type torch and an IBM PC-AT data system. It is housed in the 
Scottish Universities Research and Reactor centre, East Kilbride.
POSSIBLE SOURCES OF CONTAMINATION OF SAMPLES ANALYSED FOR 
PLATINUM CONTENT
In the analysis of samples for very low levels of a substance inadvertent 
contamination is an important factor in the consideration of the significance of the 
observations.
In this instance, the laboratories are unlikely to be a potential source of 
contamination as platinum is not utilised in either the surgery laboratory 
(preparation of plasma samples) or the anatomy, histology and animal husbandry 
laboratories (preparation of tissue samples). This a major worry in laboratories 
where platinum is regularly in use (Tothill7, personal communication).
All containers are a potential source. Values are not quoted for the 
materials utilised in any of those used. It would be likely though that if they were 
a significant a constant low level would be detected.
The acids used are not considered a potential source of platinum (though 
they contribute to the matrix effect) (Tothill and others 1990). Though it is 
possible that the glassware is a source of platinum it is an unlikely in these 
laboratories and every effort was made to clean in an appropriate way. Washing 
with acid is adequate for preparation of samples for the assessment of low levels of 
other metals such as cadmium (McDonald, personal communication8).
Cross contamination between samples was reduced to a minimum by the 
use of disposable containers, pipette tips and centrifuge tubes. At the point of 
analysis quality control is rigid to reduce this problem.
7Dr P. Tothill, Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, 
Edinburgh
8Mrs L. McDonald, Department of Veterinary Anatomy, Glasgow University Veterinary School
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STABLISHMENT OF NATURALLY OCCURRING TISSUE PLATINUM 
CONCENTRATIONS
As far as the author is aware, there are no published figures for the levels of 
platinum  in the tissues of dogs that have not been exposed to platinum. The use 
of ICP-MS technology on biological samples has only recently been described. 
Papers describing the distribution of platinum in canine tissue omit the assessment 
of the base line (Reviere and others 1990). This is probably related to the 
resolution available with the measuring techniques used. Naturally occurring 
platinum  in human blood and tissues has been described in Australia using the 
equally sensitive technique of absorptive voltammetry (Nygren and others 1990). 
Up to the development of these techniques, platinum in organisms not exposed to 
platinum  containing drugs could only be estimated using pooled sera, hair, nail 
clippings, etc. (Nygren and others 1990).
To assess the background levels of platinum plasma and tissue samples 
were obtained. Plasma from dogs not under going platinum chemotherapy was 
assessed using blood obtained at the time of sampling for clinical reasons. This 
blood was handled in the same way to that which was taken from animals during 
cisplatin chemotherapy (see page 60). Tissue samples were taken in the post 
m ortem  room of Glasgow University Veterinary School. Tissues were cut using 
the routine knives and saws available. Until they were further prepared they were 
stored in polyethylene containers at -20°C.
Tissue samples were prepared for platinum analysis by acid digest to 
remove the organic components. The fresh weight of the samples was recorded 
and they were dried to a constant weight in an oven at 110°C. Using glassware 
cleaned with nitric acid, samples were digested in 7 ml of Aristar nitric acid9, 
heated at 98 °C, until dryness. Reconstitution was to 25 ml. Initially this was with 
de-ionised water. However, for later samples this was changed to 10% Aristar 
hydrochloric acid due to technical problems with the stability of the platinum if 
m ade up with water.
Individual exposure to cisplatin was unknown but the assumption that 
exposure had not occurred was made. As this drug is both expensive and currently 
very limited in its clinical veterinary usage this is not unreasonable (it would have 
been obvious if individual had platinum levels that suggested exposure to a source 
of administered therapeutic platinum).
The mean level of plasma ultrafiltratable platinum detected in controls was 
0.35 ( + /-  0.2) ng mb1. The detection accuracy of the technique is such that these 
levels are on the very limits of detection. They are such that it was deemed
9Aristar nitric acid analysis.
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unnecessary to adjust the levels detected during the administration of the drug. At 
24 hours, the limit to which the area under the curve was calculated, detected 
levels were in excess of 15x this level. The platinum levels from individual animals 
are presented in the appendices (Table 35, page 111).
Tissue samples (kidney, bone, liver, spleen and muscle) were taken from 5 
carcasses at post mortem. No significant levels of platinum were detected.
SUMMARY:
The clinical use of cisplatin is not as extensive in the dog as it is in man. 
This is probably related to the expense, clinicians perceptions4 of the practicalities 
of its administration and the potential for toxicity
In use, it has been shown that it can be administered safely with tolerable 
toxic effects. Though renal toxicity is perceived as the most important problem 
recent reports of its use suggest that, in canine oncology, myelosuppression is an 
im portant consideration. Dogs have not been recorded as suffering from 
ototoxicity and peripheral neurotoxicity both of which of are great clinical 
importance in man. This is probably because dogs are given lower doses and 
fewer cycles. This may change as the protocols evolve. Currently the 
recommendations appear to be changing to multiple doses.
Most of the effort in the design of administration regimes in man and the 
dog are directed towards renal protection. Little work has been done on 
myelotoxicity, though it appears that techniques that protect against renal damage 
do not protect against myelosuppression.
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REVIEW OF THE LITERATURE PERTAINING TO 
THE MANAGEMENT OF OSTEOSARCOMA IN 
THE DOG
Chapter 4
CLINICAL EXPERIENCE WITH CISPLATIN IN THE DOG
Cisplatin has to present had relatively limited clinical use in veterinary 
oncology in contrast to the human field where it is one of the most important 
drugs. Though it has been applied to a number of situations in the dog (Table 20, 
68-72) it has found its greatest reported application to be in the management of 
osteosarcoma. Its efficacy has not been as dramatic in the veterinary field as it has 
been in human.
However, the use of cisplatin as a single chemotherapeutic agent, in 
conjunction with surgery, in the treatment of canine appendicular osteosarcoma 
has produced a consistent increase in patient survival. Currently median survival 
times are in the range 32-59 weeks. This compares with the survival period of 18- 
25 weeks for dogs managed by amputation alone. Though the use of historical 
controls in the analysis of the results of the management of human osteosarcoma 
has been questioned, the canine disease seems very consistent and their use is 
acceptable (Spodnick and others 1991).
PRESENT PROTOCOLS IN USE IN THE DOG FOR THE 
ADMINISTRATION OF CISPLATIN
Currently there is no agreed protocol for the clinical use of cisplatin in the 
dog. A number of reports of the use of cisplatin in a number of clinical situations 
has been described. These are detailed in Table 20 on pages 68-72. In general 
they all include the administration of fluids with preinfusion hydration and diuresis. 
The use of specific diuretics is less consistent. All papers state that the ideal 
protocol has yet to be defined.
Cisplatin is administered both intravenously (IV) and intra-arterially (IA) 
for regional perfusion of the tumour in conjunction with limb sparing. Though IA 
infusion increases the percentage tumour necrosis in comparison to IV 
administration there has been no demonstrated benefit in long term survival 
(LaRue and others 1989).
A number of authors report other chemotherapeutic regimes. These 
involve the use of drugs with accepted use in the treatm ent of osteosarcoma in 
humans. The use of doxorubicin as a single agent has been disappointing 
compared to cisplatin (Madewell and others 1978, Ogilvie and others 1989b). 
Treatm ent with methotrexate (with leucovorin rescue), cyclophosphamide and 
doxorubicin following amputation gave a median survival period of 60 weeks 
(range 12-180) (Henness and others 1977).
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Saline hydration and diuresis is identified as an important feature in the 
control of cisplatin induced renal toxicity and is a feature of all the reported 
clinical uses of cisplatin in the dog (Table 20, pages 68-72). Initially volumes of 
fluid administered were large and the time periods prolonged as experience was 
limited and clinicians were cautious. More streamlined protocols have been used 
more recently as confidence and experience have grown. A protocol described in 
experimental, healthy dogs by Oglivie and others (1988) using 0.9% saline 
adm inistered at 18.3ml kg-1 for 4 hours and 2 hours after cisplatin infusion has 
becom e the basis of many of the current administration protocols.
LIMB SALVAGE SURGERY
THE IMMUNE RESPONSE TO CORTICAL ALLOGRAFTS IN THE DOG
The literature related to the use of massive cortical allografts in the 
m anagem ent of fractures in the dog suggests that immune mediated response to 
allograft implantation does not represent a clinical problem with failures attributed 
mainly to infection and improper stabilisation of the graft (Henry and Wadsworth 
1981b, Johnson 1988).
Recognition of bone graft rejection is not well described (Friedlaender 
1991). Clinical and radiographic progress are not sensitive techniques for the 
assessment of immunological reactions in bone (Stevenson and others 1991) 
Incorporation of a graft is an active process of vascularisation, resorption and new 
bone formation. Radiographically this is seen as loss of trabecular detail and loss 
of density. This starts at the proximal and distal ends and spreads towards the 
centre of the graft. Graft-host union is usually seen 3-4 months after surgery. 
Rejection results in sequestration of the tissue or resorption without replacement 
(Johnson 1988).
There is evidence that like the transplantation of other tissues bone 
stimulates a response in the host (Friedlaender 1991). However, the low cellular 
content may result in the slow development of associated changes (Stevenson 
1987).
Burchardt and others (1978) demonstrated that in general fresh allografts 
are apparently rejected and that freeze drying does not prevent this occurring but 
does reduce the magnitude. A similar observation was made by Stevenson (1987).
It has been suggested that the primary immunogenicity lies with the bone 
marrow cells that remain (Stevenson 1987). However, work in mice suggests that 
o ther components of bone may elicit a response (Horowitz and Friedlaender
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1991). One study of the effect of freezing on immunogenicity involved the canine 
fibula, a bone having no marrow cavity in the adult dog (Burchardt and others 
1978). Tissue matching of dogs significantly reduces the immune response 
induced by allogenic bone (Stevenson 1987). Twenty percent of fresh allografts in 
Burchardt and others series (1978) were incorporated in a way histologically 
indistinguishable from fresh autografts, presumably because of unintentional tissue 
matching.
The immune response appears to have two components a complement 
dependent cell mediated cytotoxicity and a humoral component. These are 
directed against class I and II histocompatibility antigens (Stevenson 1987). 
Freezing would appear to reduce the antibody dependent humoral response more 
than the antibody dependant cell mediated cytotoxic response (Stevenson 1987). 
Experim ental immune suppression with azathioprine resulted in improved 
incorporation of canine fresh allografts again suggesting the immune response may 
be of significance (Burchardt and others 1977).
The activated T cell response to fresh murine bone allografts were cytotoxic 
C D 8+ and there appeared to be clones responding to both class I and class II 
antigens (Horowitz and Friedlaender 1991). This is an unusual response as CD8+ 
T cells usually respond to class I antigens. These ceils are known to be involved 
with the rejection of soft tissue grafts. This response occurred in the absence of 
bone marrow (a good source of both classes of histocompatibility antigens) though 
the cell types responsible for this stimulation are unknown. It is unlikely that the 
cell matrix or mineral are related to T cell activation as the antigens to which they 
respond are features of cell surfaces. The cells were possibly macrophages, which 
are a potent source of class II antigens (or osteoclasts, which might be expected to 
express class II antigens as they are of the same derivation).
The clinical significance of the immune reaction to allogenic bone in our 
patients is questionable where the major problems are apparently related to 
technical insufficiencies. It is possible though that the effects of an immune 
m ediated response may underlie these apparently straight forward clinical 
problems. The author is unaware of tissue matching being used clinically for the 
assessment of patients undergoing allograft implantation.
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LIMB SALVAGE EXPERIENCE REPORTED IN THE LITERATURE
Amputation, though the most effective way of controlling tumours locally, 
does not fulfil most surgeons4 wish to engineer a full return to function. 
Techniques to reconstruct the defect and maintain limb function following en-bloc 
resection have been described in humans (Mankin 1987b). Two basic techniques 
are described:- the use of endoprostheses and the replacement of the resected 
bone with allografts. Procedures using osteochondral grafts have also been 
described (Mankin and others 1983). Different centres appear to use and 
advocate one or other of these methods.
Endoprostheses are not readily available for the canine but the potential for 
harvesting bone for the preparation of allografts is considerable. A number of 
centres in the USA have developed the use of allografts in the management of 
canine bone tumours. The majority of this work has been performed at the 
Colorado State University and the North Carolina State University.
A technique where the resected tumour was replaced with bone cement 
containing methotrexate was unsuccessful, with those animals not succumbing to 
metastatic disease requiring amputation of the limb because of complications with 
the technique (Hagege and Hernigou 1987).
A massive cortical graft can be used to reconstruct the defect left following 
tumour resection. There are numerous reports of the successful use of allografts 
in the management of fractures in animals (Henry and Wadsworth 1981a, Sinibaldi 
1989). A cortical graft provides physical support, encourages osteoconduction and 
may stimulate osteoinduction. However, the concept of osteoinduction by grafts 
has been recently questioned and may not be a feature of the use of allografts in 
higher mammals (Schwartz and others 1991). There are no viable cells in these 
grafts to be transplanted. Incorporation of a cortical bone graft takes months to 
years and may never be completed. This means that during the period of 
incorporation it is significantly weaker than host bone. Removal of plates should 
not be contemplated within 1-2 years of grafting (Johnson 1988). A cancellous 
autograft is routinely utilised to encourage incorporation at the host interfaces.
A number of sites have been selected for limb sparing surgery. The most 
successful have been the distal radius, proximal humerus and distal tibia. 
Procedures at all these sites involves arthrodesis of the adjacent joint. Experience 
with management of tumours around the stifle is disappointing and at least one 
centre now longer attempts it (LaRue and others 1989).
The reported results suggest that if there are no complications, and post 
operative morbidity can be significant (25-35% in human patients within the first 3 
years, Stevenson and others 1991), the expected outcome for this type of surgery is 
similar to that found with the arthrodesis of the same joint for other reasons. This
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is suggested as a reason for the disappointing experiences with surgeries involving 
stifle arthrodesis. Straw and others (1990) report good to excellent limb function 
in 69% of their evaluated cases.
Complications include infection, failure of fixation and local regrowth. In 
the largest reported series of 70 dogs (Straw and others 1990) complications 
included a rate of local recurrence of 24% and an infection rate of 31%. Of the 22 
animals with allograft infection 7 required amputation with the remainder 
responding to systemic or local antibiotics (gentamycin impregnated polymethyl 
methacrylate beads). These findings highlight the potential for a considerable 
degree of morbidity associated with limb sparing surgery, even at a centre which 
has developed considerable experience. Comparison of the survival of dogs under 
going limb sparing plus chemotherapy showed no difference from a group under 
going amputation and chemotherapy.
Mankin (1987b) reports an incidence of infection of 12.4% in a series of 209 
hum an patients managed with allografts for a variety of conditions including 43 
osteosarcomas. He notes that complications were found most commonly in 
patients under going vigorous chemotherapy post surgery. Currently reported 
cases in dogs involving allografts are of animals that have had only preoperative 
chemotherapy.
Graft incorporation was observed in animals without complications (LaRue 
and others 1989). Allograft infection was the primary cause of failure 
incorporation in a series of 12 animals in which the progress was monitored
Neither of these American centres utilised post operative support (other 
than a Robert-Jones dressing for a couple of days to control swelling). How this 
aspect of management of these animals compares with their routine management 
of arthrodesis patients is not stated. Recommendations for the post operative 
m anagement of a carpal arthrodesis include the use of a cast for 6 weeks post 
surgery (Newton and Nunamaker 1984). The use of a cast following a distal joint
arthrodesis is routine at GUVS.
The staging of the tumour (Enneking system, page 8) at the time of 
presentation is significant, with IA and IB tumours having a success rate of 70% 
with this dropping to IIA and IIB tumours having a success rate of 30-40%. Most 
tumours in dogs are staged as IIB (Straw and others 1990).
Degree of tumour necrosis and prognosis
The use of preoperative chemotherapy is common in the management of 
human osteosarcomas. The primary reason is to reduce the bulk of the tumour to 
aid the surgeon at the time of resection. The degree of necrosis of the tumour at 
the time of surgery has been assessed as a prognostic indicator. Lane and Glasser
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(1987) describe techniques in which the resected tumour is examined for necrosis - 
prognosis improves with increasing degree of necrosis. It is also used to assess the 
chem otherapeutic regime and adjust it if necessary.
This relationship between tumour necrosis and survival has not been 
dem onstrated in the dog (Powers and others 1991). However, it is strongly 
predictive of the likelihood of local recurrence with 80% necrosis being the 
watershed. Less than 80% necrosis is associated with a high liklihood of local 
regrowth. There are differences between the chemotherapy strategies in dog and 
man, which may be related to this apparent difference in the predictive value of 
tum our necrosis following preoperative chemotherapy (particularly the use of post­
operative chemotherapy). Animals given radiotherapy of the primary alone would 
not expect to have their time to metastasis extended if micrometastasis was already 
present, which might be expected.
Tum our necrosis was related to the method of preoperative management. 
Canine osteosarcomas are usually spindle cell tumours and as such might be 
expected to be relatively chemo- and radio-resistant thus relatively high doses of 
radiation were administered. Radiotherapy gave the greatest tumour kill (81.6%) 
with a combination of radiotherapy followed by intra-arterial cisplatin (83.7%). 
Radiotherapy potentiated the response of the tumour to cisplatin. There was no 
difference in necrosis between untreated tumours and tumours managed with 
intravenous cisplatin (approximately 23%).
Radiotherapy alone is not to be recommended. Not only does it not 
control established metastatic disease but it also interferes with allograft 
incorporation resulting in increased failure rates (Thrall and others 1990).
Effect of cisplatin administration on graft incorporation
Cisplatin has a potent effect on DNA that is not cell cycle dependent, being 
expressed as cell death at mitosis (Shapiro 1989). A recent study in rats has shown 
it to inhibit the incorporation of allografts with vascularisation retarded and new 
bone production reduced compared to untreated controls. Depression of the bone 
marrow (a well recognised cisplatin induced toxicity) and its osteoprogenitor 
constituents may be partially responsible for this effect (Zart and others 19911).
The contribution of chemotherapy to the post-operative morbidity of 
patients receiving allografts has been alluded to. However, in the management of 
the m etastatic disease it is routine to administer repeated cycles to humans. Thus 
far it has not been so in the dog (Straw and others 1990). The reason for limiting
* D r . S .  S t e v e n s o n ,  D e p a r t m e n t  o f  O r t h o p a e d ic s ,  C a s e  W e s t e r n  R e s e r v e  U n iv e r s i t y ,  2 0 7 4  A b in g t o n  
R o a d ,  C l e v e l a n d ,  O h i o  4 4 1 0 6 ,  U S A .
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the num ber of cycles in canine osteosarcoma therapy is not discussed (a number of 
protocols for other tumours have described repeated cycles as well as some of the 
osteosarcom a protocols).
SUMMARY
Cisplatin has not attained the reputation and use in the dog that it has in 
hum an oncology. This may be related to the considerable cost of the drug, caution 
because of its reputation for toxicity, rejection because of the effort required in 
adm inistration and the less dramatic clinical effects achieved. However, it 
undoubtedly increases the survival of patients with a number of sarcomas including 
osteosarcoma. The full value of cisplatin chemotherapy in the dog has probably 
still to be established.
It has been demonstrated that it can be administered with safety and 
minimal toxicity. The toxicity associated with long term administration in humans 
have not been described in canine patient, probably because of the relatively short 
courses and lower doses. However, even the short term diuresis regime described 
by Ogilvie and others (1988) requires a substantial investment in time and 
materials.
The use of cisplatin in osteosarcoma has extended the lives of patients from 
the 18-25 weeks that might be expected following palliative amputation. Currently 
median survival periods of 32-59 weeks are reported (Table 20, pages 68-72). This 
increase in survival has been observed with periods of chemotherapy that are short 
com pared to man. It is possible the survival period may be increased by 
increasing the number of cycles administed. Occasional individuals appear to 
have very long periods of remission reminiscent of the animals that are apparently 
cured by amputation.
76
CHAPTER 5.
ANALYSIS OF RESULTS
Chapter 5
This chapter summarises the clinical outcome and pharmacokinetics of the 
platinum in plasma of a number of cases of appendicular osteosarcoma treated in 
the Surgery Departm ent at Glasgow University Veterinary School. Not all cases 
treated had samples taken for platinum analysis.
HANDLING OF CISPLATIN
In common with many chemotherapeutics cisplatin is a hazard to personnel 
who handle it. It is known to be a mutagen, carcinogen, teratogen and an irritant 
to mucus membranes (Swanson 1988). Though these effects have not been 
quantified in humans (Lederle Laboratories 1986) (though observed in animal 
experiments) it is considered unacceptable to wait for the accumulation of such 
evidence in the human population before suggesting precautions to be taken whilst 
working with it (Blue Sheet Drug Report 22, 1979 cited by Swanson 1988).
Cisplatin is made available as a lyophilised powder in glass vials (lOmg and 
50mg) with rubber seals1. It is reconstituted by the introduction of water for 
injection. Pressure rises in the bottle during this process and there is a danger of 
aerolisation as the needle is withdrawn. Care was taken to equalise the pressure 
before withdrawal of the syringe by aspirating gas into the syringe used to 
introduce the water. Whilst handling the drug staff wore a surgical mask and latex 
gloves.
It is known that platinum containing metabolites of the drug are excreted in 
the urine. In many centres drug infusion is carried out in a metabolic cage to 
make management of the excreta more straight forward. Such facilities were not 
available at GUVS and in an effort to control soiling kennels were generously 
bedded with newspaper. Patients were given frequent opportunities to void urine 
in the run. Contaminated newspaper was handled by staff wearing heavy duty 
rubber gloves. Urine passed in the run was washed away with copious amounts of 
water.
ADMINISTRATION OF CISPLATIN
Steel needles were used to add water for rehydration of the drug 
(aluminium inactivates cisplatin, Lederle Laboratories 1986). This was done 
immediately before infusion as cisplatin has limited stability once reconstituted 
(Lederle Laboratories 1986). The calculated dose of cisplatin was made up in 
sufficient 0.9% saline to give a 20 minute infusion at the rate of lOml/kg/hr.
C i s p l a t i n ,  L e d e r a l e  la b o r a t r ie s ,  C y a n a m id  o f  G r e a t  B r it ia n  L td ., F a r e h a m  R o a d ,  G o s p o r t ,  
H a m p s h i r e ,  P 0 1 3  O A S .
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Patients were not fed on the morning of infusion but were allowed free 
access to drinking water. To minimise the chance of catheters being pulled free 
during the infusion excitable patients were sedated, using a cocktail of 
aceprom azine2 (0.05mg/kg) and buprenorphine3 (O.Olmg/kg) given 
intramuscularly. This was repeated if required. Patients from whom samples for 
platinum  analysis were collected were not sedated.
Prior to infusion patients were hydrated with 0.9% saline for 4 hours at a 
rate of lOml/kg/hr. Fluids were administered using a Travenol4 Flo-Guard 6200 
peristaltic infusion pump. At the end of this period they were exercised for a brief 
period to allow urination.
Prior to infusion one of two diuretics was administered:
• mannitol, 0.5g/kg as a slow intravenous injection
• frusemide (Lasix, Hoechst5) 0.5mg/kg intravenously
followed by the anti-emetic metoclopramide (Emequell, Beechams6) lm g/kg by 
slow intravenous injection.
Following infusion of the cisplatin fluid administration was continued for a 
further 2 hours at lOml/kg/hr. Patients were fed approximately 6 hours post 
infusion.
MEASUREMENT OF RENAL FUNCTION
It was felt that an estimation of renal function would be useful as it was 
intended to give multiple doses of the drug. Clinical experience in dogs has shown 
decreasing renal function with repeated doses (Shapiro and others 1988a). 
Calvert and others (1989) had demonstrated the dramatic effect that renal 
insufficiency could have on the pharmacokinetics of carboplatin.
Creatinine clearance has been shown to be an insensitive technique in this 
type of work in humans and has been discredited. The current recommendations 
are for a technique involving ^Cr-ED TA  which has been demonstrated to be very 
sensitive (Daugaard and Abildgaard 1989).
2A C P ,  C - V e t  L td . ,  B u r y  S t . E d m u n d s ,  N o r f o lk
3T e m g e s i c ,  R e c k i t t  a n d  C o lm a n ,  D a n s o m  L a n e ,  H u l l  H U 8  7 D S
4T r a v e n o l  L a b o r a t o r i e s  L td ., T h e t f o r d ,  N o r f o lk .
5 L a s ix ,  H o e c h s t  U K  L td ., P h a r m a c e u t ic a l  D iv is io n ,  H o e c h s t  H o u s e ,  S a ls ib u r y  R o a d ,  H o n s lo w ,  
M i d d l e s e x ,  T W 4  6 J H .
‘ E m e q u e l l ,  B e e c h a m  R e s e a r c h  L a b o r a t o r ie s ,  G r e a t  W e s t e r n  R o a d , B r e n t f o r d ,  M id d l e s e x ,  T W 8  
9 B D .
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Initially plans were made to measure creatinine clearance as this was the
only functional test feasible in the clinical situation at GUVS. This was to be a
short version performed over a period of 3 hours as a metabolic cage required for
the 24 hour technique was not available. A number of trial runs were made to
assess the practicality of this technique and it was shown to be so wildly variable 
that it was abandoned.
There is a also a problem with creatinine clearance in male dogs in which 
the secretion of creatinine into the tubules can lead to overestimation of GFR 
(Chew and Dibartola 1989). This can be accommodated for in the calculations but 
compromises further a technique that is insensitive. As renal mass decreases 
secretion increases making the estimation of GFR less accurate as renal disease 
advances.
As the labelled chromium technique was not available in the Department it 
was elected not to pursue renal function. Blood urea and serum creatinine were 
m easured as a guide to severe renal dysfunction (a rise in these parameters implies 
75% of the nephrons are compromised).
SELECTION OF PATIENTS
The selection of patients to be included within a clinical trial can 
dramatically influence the outcome (McEwan 1989b). Individuals were selected 
with respect to the following criteria:
• histologically confirmed osteosarcoma (biopsy)
• no other pathology that might be expected to reduce remaining life span to less 
than one year
• no sign of disseminated neoplastic disease (survey radiographs of the thorax 
and abdomen)
• renal function not significantly impaired (page 79)
• no apparent impairment bone marrow function (routine haematology)
• client assessment
Table 21. Selection criteria for patients managed with cisplatin at Glasgow
University Veterinary School.
AIMS OF INVESTIGATION
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The ideal dose regime of cisplatin in both man and the dog has yet to be 
established. Though clinical efficacy can be compared between regimes(see 
conclusions), a thorough understanding of the pharmacokinetics of the drug in the 
treatm ent of canine osteosarcoma has yet to be considered.
Currently drug dose appears to be the largest physical dose that results in 
acceptable toxicity. There is a steep dose-response curve with a number of 
tum our types but increasing dose is complicated by toxicity. There is evidence that 
prolonged exposure may be more relevant than peak levels achieved (Drewinko 
and others 1973, Gandara and others 1989). The area under the concentration­
time curve for prolonged infusions as opposed to push infusions is greater with 
decreased urinary excretion suggesting greater body retention (Gullo and others 
1980, Saito and others 1990).
The area under the concentration-time curve (AUC) is used in 
pharmacology as a measure of exposure to a drug. As cisplatin is effectively 
irreversibly protein bound it was decided to assess the AUC for the unbound 
fraction of the drug. It was felt that the AUC might be a useful parameter in the 
comparison of administration protocols. It is known that for a given protocol the 
AUC shares a linear relationship with the dose administered (Riviere and others 
1990). Peak levels of platinum were also assessed as these have been related to 
nephrotoxicity (Campbell and others 1983). Platinum was measured between 
cycles, where possible, for evidence of persistence.
Platinum concentration is used as an estimate of cisplatin concentration. 
The two param eters are not directly related as cisplatin undergoes aquation into a 
num ber of derivatives in the plasma. Using techniques that specifically identify 
cisplatin it is thought that during the 2 hours immediately post infusion the 
platinum in the ultrafiltrate represents unchanged drug but by 4 hours the bulk of 
the platinum detected is in the form of aquation products (Reece and others 1987). 
In the rat it has been shown that the proportion of cisplatin that is present in the 
pool of platinum in the plasma ultrafiltrate after 3 hours is in the order of 1% of 
that at 15 minutes after injection (Daley-Yates 1985).
The fate of cisplatin administered to these patients cannot be followed as 
there is no information on total plasma platinum or excretion. If these parameters 
are followed in conjunction a picture of tissue take-up can be established (Dumas
and others 1990).
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The elimination of plasma platinum from the body of dogs following the 
administration of cisplatin has been shown to be bi-phasic with a t^ 9 ot of less than 
1 hour and t lj2 (3 of 4-5 days. Within 4 hours following an intravenous bolus 
plasma levels were 90% reduced and 60-70% of the administered dose was 
recovered in the urine. There was little change in the plasma platinum 
concentration between day 4 and day 12 (Litterst and others 1976). The decay of 
ultrafiltratable platinum in humans following infusion of cisplatin has been 
described Table 18 (page 43). It varies with the dose and the protocol of 
administration but is the region of 20-30 minutes.
The intention was to assesses the AUC for the platinum in the plasma 
ultrafiltrate achieved by our administration protocol. The author was not aware of 
information pertaining to what to expect for the administration of this dose as an 
infusion in the dog. Experimental work with cisplatin tends to involve bolus 
administration. However, it appeared likely that the greatest changes would be 
observed during the infusion and in the four hours following it. Little change over 
the period 24 hours to 3 weeks was expected. It was not certain that platinum 
would be detected in the plasma ultrafiltrate during this period as the plasma 
platinum might be expected to be protein bound. Samples during this period were 
taken in conjunction with routine samples required for haematological monitoring. 
The time intervals selected are presented in Table 23 (page 84).
DATA FROM CISPLATIN ADMINISTRATION TO PATIENTS AT 
GLASGOW UNIVERSITY VETERINARY SCHOOL
PATIENT DETAILS
Patient details for cases of primary bone tumours managed with cisplatin 
are summarised in Table 22 (page 83). This series of dogs have similar 
characteristics to those reported in the literature. With one exception (case 
number (110232) they were large and giant breed dogs, with an mean weight of 40 
kg. They were mostly male (5/7). The mean age was 6.9 years. There were 6 
osteosarcomas and 1 chondrosarcoma. The tumours were classified as IIB (with 
one exception, case number 110809 which was classified as IB) using the Enneking
system.
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start of infusion
end of infusion 
decay period
Time Time
(minutes) (hours and weeks)
0
2
5
10
15
20
2
5
10
15
30
60 1 hour
120 2
240 4
360 6
480 8
720 12
1440 24
10080 1 week
20160 2
30240 3
Table 23. Time points selected for the assessment of the decay of ultrafiltratable 
platinum after administration of cisplatin as a 20 minute infusion.
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PHARMACOKINETICS OF PLATINUM IN THE PLASMA ULTRAFILTRATE
The plasma ultrafiltrate platinum concentrations for these patients are 
presented in the appendices (Tables 36-38, pages 112-118) and as semi-log graphs 
(Figures 6-10, pages 88-92). The peak concentrations are in Table 24 and the 
pharm acokinetic data in Table 26 (page 87).
Case Number Cycle Dose of cisplatin Peak [free
(mg m 2)_______ platinum] ng m l1
1 1 4 9 9 3 1 6 0 2 9 1 6 .5 0
2 4 0 8 8 2 .4 0
3 4 0 1 2 4 9 .8 0
4 4 0 in f o r m a t io n  n o t  a v a i la b le
1 1 5 9 3 0 1 6 0 1 3 4 0 .6 9
2 4 0 in f o r m a t io n  n o t  a v a i la b le
1 1 6 7 9 9 1 4 0 1 5 9 7 .2 5
2 6 0 2 0 7 8 .3 6
Table 24. Peak concentrations of free platinum in the plasma of patients given
cisplatin chemotherapy.
PHARMACOKINETIC DATA
Peak concentrations were observed around the end of the cisplatin infusion. 
The m ean peak concentration at 40 mg n r2 was 1451.95 ng mb1 plasma (range 
882.40-1597.25) and at 60 mg n r2 was 2128.59 ng mb1 (range 1340.69-2916.50).
The pharmacokinetic analysis of the ultrafiltratable platinum 
concentrations was performed by Dr A. Kellman using a software package 
Status37. Visual inspection of the decay curves suggests a three exponential decay. 
However, analysis of the data was unable to accommodate the long terminal half 
life into a decay model. The graph in Figure 7 has been plotted to include the 
long term inal halflife. This was the only instance where the computer model 
would accept it. The best fit was to a two exponential model with a mean ilj2 cc for 
40 mg m-2 of 9.5 minutes (range 1.9-15.1) t1/2P for 40 mg n r2 of 29.2 minutes
(range 18.1-40.4).
7S t a t u s 3 ,  D r .A .K e l l m a n ,  D e p a r t m e n t  o f  M e d e c in e  a n d  T h e r a p u t ic s ,  G la s g o w  U n iv e r s i t y  M e d ic a l  
S c h o o l
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The AUC for the ultrafiltratable plasma platinum concentration curve is 
consistent for 40mg m-2 at 4.7 x 104 ng min-> mh> (range 4.3-4.9). The AUC, is as 
expected, increased by an increase in the dose (Riviere and others 1990). A 50% 
increase in the dose of cisplatin resulted in 80% increase in the AUC.
The klO represents the rate at which the platinum is eliminated from the 
central com partm ent, and assumes that all drug elimination occurs via this 
compartment. It remains reasonably constant across the individual cycles.
The clearance represents the volume of plasma cleared of platinum per unit 
time. For individuals this would appear to be remarkably consistent and over the 
cycles in all the patients it appears to remain fairly constant.
The volume at a steady state (Vdss) is achieved when the rate of 
adm inistration equals the rate of elimination and the compartments are in 
equilibrium. The mean value of Vdss for the ultrafiltratable platinum after 40 mg 
n r2 430 ml kg-1 (range 430-890).
The apparent volume of distribution is related to distribution through the 
body. Drugs that are unable to leave the central compartment, for example as the 
result of binding, have a smaller volume than those that can penetrate other tissues 
as will those that are concentrated for any reason. The volume will also be 
increased by tissue take up. Very lipid soluble drugs, for example many injectable 
anaesthetic agents, have a very high volume distribution suggesting concentration.
PERSISTENCE OF PLATINUM
Analysis of samples taken at periods of 1, 2 and 3 weeks post infusion 
showed the persistence of platinum in the plasma ultrafiltrate (Table 25).
Time Average, with standard deviation, and range of platinum
(weeks) concentrations in plasma ultrafiltrate (ng m l1)____
1 3 .4 3  +  / -  1 .4 8 ( 1 .5 2 - 4 .7 5 )
2  1 .8 6  + / -  1 .0 6 ( 0 .6 5 - 3 .0 5 )
_________ 3  1 .7 4  + / -  1 .4 6 ( 0 .5 5 - 4 .2 9 ) ______________________
Table 25. Persistence of platinum in the plasma ultrafiltrate.
Case number 116799 was sampled 6 weeks post chemotherapy at which a 
level of 1.49 ng ml*1 was detected. This suggests that the decay slows further after
1 week. It must be remembered that some of these samples were haemolysed (see 
page 58).
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Platinum
Log10( Pt(ng/ml))
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Figure 6. Log graph of piasma ultrafiltrate platinum concentration for case
number 114993. Cisplatin @ 40mg m“2,2 nd cycle.
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Platinum
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Figure 7. Log graph of plasma ultrafiltrate platinum concentration for case 
number 114993. Cisplatin @ 40mg nr2,3 rd cycle
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Platinum
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Figure 8. Log graph of plasma ultrafiltrate platinum concentration for case
number 115930. Cisplatin @ 60 mg m '2,1st cycle.
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Figure 9. Log graph of plasma ultrafiltrate platinum concentration for case
number 116799. Cisplatin @ 40mg m“2,1 st cycle.
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Figure 10. Log graph of plasma ultrafiltrate platinum concentration for case
number 116799. Cisplatin @ 60 mg nr2,2 nd cycle.
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Platinum  tissue levels are recorded from case number 115930 (Tables 27 
and 28, page 95). This dog was managed with a preoperative dose of cisplatin 
followed by amputation and chemotherapy 32 days later. It was euthanased 143 
days after diagnosis, which was 105 days after the second course of cisplatin, due to 
pain resulting from metastasis to the proximal femur. Tissue samples were 
analysed for platinum concentrations from the leg at the time of amputation and 
from the carcass at post mortem.
Interestingly the tissue platinum levels in the tumour at resection vary by a 
factor of 2. Sections taken of the samples submitted for analysis show the area 
with the lowest platinum concentration to be oedematous and have a dense plasma 
cell infiltrate of the tumour, whilst the highest concentration was an area with little 
infiltrate and probably periosteal response rather than tumour8. Distribution 
amongst the normal tissues at post mortem was similar to that described by Litterst 
and others (1976). There is a trend for metastases to contain less platinum than 
the surrounding parenchyma.
TOXIC EFFECTS OBSERVED IN PATIENTS TREATED AT GLASGOW 
UNIVERSITY VETERINARY SCHOOL
Patients undergoing cisplatin chemotherapy were monitored for toxic side 
effects of the drug. This involved:
1. weekly assessment of routine haematology
2. weekly assessment of routine biochemistry
3. observation for potential gastrointestinal problems
4. urinalysis if renal problem suspected
This routine was modified for individuals not within a convenient distance 
of GUVS. These animals were not sampled until presented for chemotherapy at 
which time haematology and biochemistry were reassessed before chemotherapy 
administration. Renal function per se was not assessed.
The toxic effects observed in these patients is summarised in Table 29 on 
page 96 to 98. Toxicity was encountered in the management of all cases (5) for 
which suitable data is recorded (Table 29). This was mild in one individual 
(110809, limited to vomiting) but was significant enough to lead to reduction of the
8Professor H. P i r ie ,  D e p a r t m e n t  of V e t e r in a r y  P a t h o lo g y ,  G la s g o w  U n iv e r s it y  V e t e r in a r y  S c h o o l
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dose in the o ther four cases. Renal toxicity was only a clinical evident in one case 
( 1 1 5 9 0 3 )  and recovered in time. Myelosuppression was the most significant side 
effect. Both granulocytopaenia and thrombocytopaenia were noted ( 1 1 4 3 2 4 ,  
1 1 4 9 9 3 ,  1 1 5 9 0 3 ,  1 1 6 7 9 9 ) .  These did not necessarily occur concurrently or in every 
cycle given to an individual. Granulocytopaenia was defined as a total neutrophil 
count of less than 3 X 1 0 9 ! ' 1 and thrombocytopaenia as less than 2 0 0 X 1 0 12 ' 1 . 
Granulocytopaenia was complicated with infection in one instance ( 1 1 4 9 9 3 ) .  
M anagem ent with intravenous antibiotics (amoxycillin with clavulanic acid9) and 
supportive fluids was effective.
No o ther significant side effects were noted.
n on t \A W e r n  R o a d , B r e n t fo r d , M id d le s e x ,  T W 8
9A u g m e n t i n ,  B e e c h a m  R e s e a r c h  L a b o r a to r ie s ,  r
9BD.
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Sample Pt concentration in 
acid digest 
(ng m g 1)
Dry weight 
(mg)
Pt concentration in 
sample dry weight 
(ng m g 1)
tu m o u r  ( 1 ) 8 .5 3 0 .9 9 2 1 5 .4 0
tu m o u r  ( 2 ) 1 3 .0 4 1 .9 2 1 6 9 .8 8
tu m o u r  ( 3 ) 6 .2 1 0 .4 4 3 5 5 .2 6
n o r m a l m u s c le 8 .7 4 1 .9 7 1 1 0 .8 6
n o r m a l b o n e 1 0 .4 4 1 .6 9 1 5 4 .8 0
Table 27. Platinum concentrations in tissue samples from the foreleg of case 
number 115930 taken at the time of amputation.
Sample Pt concentration in 
acid digest 
(ng m g1)
Dry weight 
(mg)
Pt concentration in 
sample diy weight 
(ng m g1)
k id n e y  n o r m a l 5 1 .8 3 0 .3 1 4 1 7 9 .8 4
liv e r  n o r m a l 4 1 .8 6 0 .3 7 2 8 6 7 .1 2
s p le e n  n o r m a l 1 7 .8 1 0 .4 3 1 0 3 3 .0 6
lu n g  n o r m a l 6 .5 9 0 .3 0 5 4 3 .7 3
m u s c le  n o r m a l 6 .4 2 0 .5 4 2 9 8 .3 3
b o n e  n o r m a l 7 .4 5 1 .6 7 1 1 1 .7 9
liv e r  m e t 1 .2 7 0 .0 3 1 0 9 4 .8 3
s p le e n  m e t 0 .7 6 0 .3 9 4 9 .3 5
lu n g  m e t 0 .4 4 0 .2 7 4 0 .2 9
Table 28. Tissue platinum levels at post mortem of case number 115930.
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SURVIVAL BENEFITS OF CISPLATIN CHEMOTHERAPEUTIC 
PROTOCOL
It is im portant to realise that the disease free interval is a function of the 
investigative process (time to presentation, frequency of check radiographs, etc.) 
and that the survival time is influenced by the clients attitude to the timing of 
euthanasia.
Interval ___________ Definition____________________________
d i s e a s e  f r e e  in t e r v a l  t im e  f r o m  d a t e  o f  b i o p s y  c o n f i r m i n g  l e s i o n  t o
d e t e c t a b l e  m e t a s t a s i s
s u r v iv a l  t im e  f r o m  d a t e  o f  b i o p s y  c o n f i r m i n g  l e s i o n  t o
d e a t h
Table 30. Definition of disease free interval (DFI) and survival used in this
dissertation.
The details of patients managed for primary bone tumours at GUVS, using 
a com bination of surgery and cisplatin chemotherapy, are presented in Table 22 
(page 83). All tumours were reviewed "blind" by a veterinary pathologist and 
classified on cellular morphology after Rosens‘s criteria (Table 6, page 9)10. They 
were osteosarcomas, with the exception of case num ber 116799 which was 
classified as a chondrosarcoma. All the osteosarcomas, with one exception, were 
classified as high grade spindle cell sarcomas. The chondrosarcoma was classified 
as a high grade spindle cell sarcoma.
Disease free interval (median, weeks)_______ Survival time (median, weeks)
16.8 22.7
Table 31. Survival and disease free interval for cases of osteosarcoma managed 
surgeiy and chemotherapy at Glasgow University Veterinaiy School.
The median disease free interval was 16.8 weeks (range 7.4-52.6) and the 
m edian survival period was 22.7 (range 11.3-75.3) (Table 31). Q uoted survival 
periods in the literature range from 32-59 weeks.
Case num ber 110809 had sequential material available for histological 
examination :- the original biopsy at the time of diagnosis; a second biopsy from a 
suspected regrowth; material taken at post mortem. The initial material was less
10D r .  I .A .P .  M c C a n d l i s h ,  D e p a r t m e n t  o f  V e t e r ia n r y  P a t h o lo g y ,  G l a s g o w  U n iv e r s i t y  V e t e r in a r y  S c h o o l
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aggressive compared to samples examined from other cases and was classified as a 
low grade spindle cell sarcoma. Later material had a progressively more 
aggressive appearance.
EXPERIENCES WITH LIMB SALVAGE AT GLASGOW 
UNIVERSITY VETERINARY SCHOOL
Five patients underwent limb salvage surgery. Animals with suitable 
tumours of either the distal radius or tibia were selected. The criteria for the 
selection of patients were similar to those described by Straw and others 1990 
(Table 32).
• confirmed osteosarcoma of distal radius or tibia with minimal soft tissue 
involvement
• not involving greater than 50% of diaphyseal length
• no evidence of metastatic disease
• no evidence of complicating or life threatening systemic disease
• owners who were committed to the procedure and aware of potential problems
Table 32. Criteria for the selection of patients for limb sparing surgery.
A bone bank was established following the recommendations of Johnson
(1988). Allografts were obtained from retired racing greyhounds. These were to 
be culled because of chronic injuries and had been donated to the D epartm ent of 
Surgery. Donors were assessed by clinical examination and routine haematology 
and biochemistry samples were evaluated. Animals showing signs of significant 
local or systemic disease were rejected. It was elected to use the femur as it was 
felt that it would be the most useful considering the range of size in potential 
patients.
Donors were anaesthetised and prepared for aseptic surgery. At the time 
of draping the animal was euthanased with an overdose of barbiturate11 given 
intravenously. The femurs were approached routinely and the bone exposed. It 
was divided at the two metaphyses and the diaphysis removed. This was denuded 
of soft tissues, periosteum and bone marrow with a rasp. A routine bacteriology 
swab was submitted for culture. Grafts were double wrapped in sterile bags, 
radiographed for the bone bank library and deep frozen. Storage was at -20°C for 
a maximum of 6 months.
n Euthatal, RMB Animal Health, Rainham Road South, Dagenham, Essex RM10 7XS.
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At the time of surgery grafts were defrosted at room tem perature. 
Tum ours were resected form the distal joint to a point 5 cm proximal to the extent 
of the changes identified on the radiograph (LaRue and others 1989). This was 
m easured on the patients bone from the joint surface. Grafts were cut to size. 
They were stabilised in the defect with a dynamic compression plate used in a 
loaded fashion12. Care was taken to engage the recommended num ber of cortices 
proximal and distal to maximise stability (Sinibaldi 1989).
Patients were supported in a Robert-Jones dressing for the immediate 
post-operative period until the swelling had subsided. They were managed 
subsequently in a resin impregnated cast13 for periods of around 10 weeks. The 
decision on whether to remove the cast was made on radiographic progress of graft 
incorporation. Three of the patients remained in an external support because of 
the development of complications.
Graft incorporation occurred in 4 cases. This tended to happen at the 
distal end first. This was identified radiographically as confluence of the 
trabecular pattern. Grafts were united in the period 6-19 weeks. The body of the 
grafts showed, at a varying rates, loss of detail in trabecular pattern  and cortex 
definition. These changes are summarised in Table 33 (page 102). 
COMPLICATIONS
Four of the five patients managed with allograft incorporation developed 
problems associated with their grafts. These problems included infection, local 
recurrence and fixation failure.
Infection
Three of the five allografts showed evidence of infection case numbers 
110809, 114324, 114993). This was delayed in onset occurring between 8 and 16 
weeks after surgery.
The classic signs of infection with local swelling, pain and discharge from 
the area were seen. Radiographic changes were obvious in the host bone. The 
graft appeared to respond by an increased rate of lysis that was focal in nature. As 
two of these cases also experienced local regrowth interpretation is difficult (case 
numbers 110809 and 114993). The development of infection led to the late 
diagnosis of the regrowth
12S y n t h e s ,  2 0  T e w in  R o a d ,  W e lw y n  G a r d e n  C ity , H e r t f o r d s h ir e ,  A L 7  1 L G
13S c o t c h c a s t  2 ,  3 M ,
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Local recurrence
Evidence of local recurrence was observed in two cases. In both cases this 
was of clinical significance. In one case (110809) this was managed by fore 
quarter amputation as there was no evidence of metastasis at the time of diagnosis. 
In the other case (114993) the regrowth was discovered at post m ortem  (the limb 
having under gone multiple surgeries for chronic infection).
Fixation failure
Fixation failure, other than related to allograft infection and regrowth, was 
seen in a G reat Dane (case number 112509). This occurred rapidly, within 4 
weeks of surgery, at which time the radius and ulna were markedly porotic and 
deform ed under loading by the implants. This animal died of possibly unrelated 
reasons before the significance of this on her long term survival could be assessed 
(myelosuppression is a possibility as death was reported to be as a result of a lung 
infection approximately 10 days post chemotherapy, in contact dogs also 
succumbed). However, it would be fair to assume it was likely to have been 
significant.
Proximal implant loosening also occurred in two other cases. Infection and 
local regrowth were present in both instances.
Pattern of metastasis
Three dogs underwent post mortem examination the distribution of 
m etastatic disease found is summarised in Table 34. Two animals exhibited 
metastasis to organs other than the lungs (case numbers 114903 and 115930). One 
animal, case number 115930, had a metastatic deposit in the proximal femur.
Case number Distribution of metastatic deposits
1 1 0 8 0 9
1 1 4 9 0 3
1 1 5 9 3 0
Table 34. Distribution of metastatic disease in cases which underwent post
mortem.
local recurrence at amputation site (at the 
time of amputation there was tumour present 
in the axillary lymph node) extending into 
mediastinum, multiple deposits in lungs, no 
macroscopic deposits identified elsewhere 
local recurrence at site of tumour resection, 
lungs, liver, spleen, both kidneys, adrenal 
lungs, liver, spleen, kidneys, proximal femur
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SUMMARY
The median survival periods of reported series of osteosarcoma range from 
32-59 weeks (Table 20, pages 68-72). The survival periods achieved with this 
protocol are not as encouraging (median 22.7 weeks, range 11.8-75.3). These 
figures are based on a small number of patients and it is possible that with the 
treatm ent of greater numbers the survival period may be longer. Case numbers 
110809 and 114993 had an encouraging post operative survival periods. The 
significance of tumour recurrence after limb salvage is uncertain with respect to 
the development of metastatic disease is uncertain. However, metastasis to the 
axillary lymph node in case number 110809 was probably significant in its survival 
period.
The area under the concentration-time curve (AUC) was remarkably 
consistent at a dose rate of 40 mg m2 and was increased with a higher dose. Peak 
platinum concentrations were much more variable. As this value seems to change 
rapidly more frequent sampling might be important around the end of the infusion 
to establish the maximum value. Interestingly, the patient who was apparently 
exposed to the greatest peak in free platinum suffered the greatest degree of 
myelosuppression. The AUCs calculated for these cases are considerably higher 
than those for human patients given substantially greater doses ( 4 X 1 0 4 as opposed 
to 0 . 0 8  ng min H). The reason for this is not known. It is possible that it is 
related to the method of calculation.
The effect of dose on parameters such as clearance and elimination half 
lives was not investigated. However, examination of Table 26 (page 87) suggests 
that these are fairly constant for the range of doses used here. The half lives 
observed in these patients are similar to that seen in man (Table 18, page 43). 
Clearance (mean 0.0151 mim1 kg'1) is similar to that reported by Hardie and others 
(1991) for dogs who recorded the equivalent of 0.0171 mim1 kg-1 after an 
intravenous dose of 90 mg n r2 given over 5 minutes. The Vdss (mean 0.521 mim1 
kg-1) is also in a similar range to that reported in that experimental study where it 
was quoted as the equivalent of 0.6141 kg-1. The Vdss of the platinum in the 
plasma ultrafiltrate is greater than that of strongly bound drugs such as flunixin 
(0.141 kg-1, McKellar and others 1990) and less than that of a lipid soluble drug 
such as propofol (>31 kg"1, Nolan and Reid 1991).
The persistence of platinum in the plasma ultrafiltrate has not been 
described before in the dog. The history of the platinum measured is uncertain. 
It is thought that the platinum binds to constituents of the plasma smaller than 
protein (which pass through the filtration cones). W hether the detected platinum 
relates to drug complexes formed at the time of infusion, bound to a substance
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with a long half life, or whether these levels are related to the turn over of 
substances to which the platinum bound is unknown.
Platinum distribution in the carcass of case num ber 115930 was similar to 
that reported in experimental animals. Metastatic deposits in this case exhibit a 
trend for containing less platinum than the surrounding parenchyma. This 
suggests that they have been exposed to less platinum and thus presumably 
developed after the last cisplatin cycle. In contrast, one deposit (in the liver) has 
high platinum levels suggesting its presence at the time of at least one cycle.
The administration protocol used in these cases resulted in significant 
myelosuppression at 40 and 60 mg m2. Clinically evident renal toxicity occurred in 
one patient and a transient rise in BUN and creatinine were observed after doses 
of 60 mg m2. There are a number of reports of larger doses in the literature 
involving both greater and lesser rates of fluid administration which have not been 
associated with this degree of myelotoxicity. It is in the understanding of findings 
such as these that the publication of pharmacokinetic data with reports of clinical 
usage would be useful.
Few of the cases were necropsied. However, two of the three animals that 
were exhibited the wider pattern of metastasis that is associated with 
chemotherapy in both man and animals.
Limb salvage surgery at GUVS was associated with a high rate of morbidity. 
Reports of limb salvage surgery in both man and the dog suggest that if it is 
successful patients do well, but complications such as infection and regrowth lead 
to multiple procedures and in many cases amputation. Reported rates of regrowth 
are much higher in the dog than man. Morbidity associated with this type of 
surgery even in experienced centres can be high. The goals of managem ent of this 
disease are to eliminate the tumour and the metastatic deposits that are an early 
development in its natural history. If limb salvage techniques are associated with 
a high incidence of local recurrence the first goal is not being achieved (Winkler 
1991).
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CONCLUSIONS
The aims of the work presented in this dissertation were:
Conclusions
1. to assess the benefit of cisplatin chemotherapy, as a method of the managem ent 
of m etastatic disease in the treatm ent of canine osteosarcoma, in the clinic of 
Glasgow University Veterinary School
2. a preliminary investigation of the pharmacokinetics of cisplatin administration 
in the clinical situation (the area under the platinum in plasma ultrafiltrate 
concentration-time curve) and its potential as a method of comparing 
therapeutic protocols between centres
3. to assess the technique of long bone reconstruction, following tumour resection, 
with allografts in conjunction with cisplatin chemotherapy
With any study of this nature, due to the limited number of clinical cases, it 
is difficult to make broad generalisations or recommendations. The following 
conclusions are however pertinent.
Comparing the outcome of cancer chemotherapy trials conducted at different 
centres
The comparison of clinical trials conducted at different centres is fraught 
with complications. Ultimately the most im portant feature is the survival period. 
The best statistical parameters to compare are survival curves (McEwan 1989b) 
(e.g. the Kaplan-Meier curve), rather than averages, though these are not routinely 
quoted at present in the veterinary literature. The median is a more useful 
average than the mean and is currently the most quoted statistic and was thus used 
in this study.
Ideally, the cohorts of animals compared should be matched for factors such 
as age, tum our staging, etc. For instance, it has been shown that old and young 
animals have a generally poorer prognosis than middle aged individuals (Spodnick 
and others 1991). There is evidence that the metastatic potential varies between 
individual tumours in the dog, though this has not been well characterised and it is 
possible that there may be a variation in sensitivity to cisplatin. As the 
understanding of the behaviour of osteosarcoma becomes better understood the 
m ore complex will become the analysis of its management.
The interpretation of results across multiple centres would benefit from a 
routine trial design. Currently this is not the case for osteosarcoma though some 
large collaborative groups exist in North America.
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Factors that may be of significance in the design of a chemotherapeutic regime for 
cisplatin in the dog
Dose size and intensity have been shown to be im portant considerations in 
the design of therapeutic protocols in man. The ideals have yet to be established 
in the dog. Examination of Table 20 (pages 68-72) suggests that frequency of 
administration may be more significant than dose with the greatest median survival 
periods following multiple cycles of cisplatin. A dose of 50 mg n r2 given as 6 
cycles appears to be more efficacious than 70mg n r2 given as 2 cycles. The very 
long infusions used in man (5 days) are probably not a practical proposition in the 
dog.
The vehicle of administration is significant. The use of saline stabilises 
cisplatin chemically reducing aquation reactions in the plasma. This reduces the 
production of potentially toxic products. The use of hypertonic saline is significant 
in not only allowing greater doses to be used (renal protection, though still 
potential problems with the other toxic effects in humans) but also encourages 
tissue uptake which is probably relevant therapeutically.
Time of administration would appear to be im portant both with respect to 
renal toxicity and increasing retention of platinum. The most advantageous time 
is the afternoon. The practicalities of the current standard protocol (Ogilvie and 
others 1988) with a 4 hour pre-hydration period means that this is the most 
convenient time as well. This is likely to encourage standardisation.
Renal toxicity is now well controlled through the design of administration 
protocol. Myelosuppression would appear to be a greater clinical problem. At 
present there are no techniques for ameliorating this problem in the dog other 
than reducing the dose administered.
The distribution of cisplatin following intravenous administration is not 
ideal in that the take-up by the lungs is not as great as other tissues. As the lung is 
the primary area for metastatic disease techniques to maximise this may be useful, 
though the relationship between tissue platinum levels and metastatic cytotoxicity 
is unknown. Whole body hyperthermia alters the distribution of platinum in 
favour of the lungs (Riviere and others 1990). The distribution to tissues can also 
be manipulated by altering the character of the cisplatin infusion. An increasing 
exponential infusion will give significantly higher concentrations of platinum in the 
lungs compared to a bolus injection (Page, personal communication1).
!R.Page, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, 
2 7 6 0 6 .
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The use of the area under the concentration-time curve (AUC) for platinum in 
plasma ultrafiltrate in the analysis of cisplatin administration protocols
In isolation this information is of limited value. It will give an impression 
of whether tissue exposure has been of a similar order but gives no information on 
the retention of platinum by the tissues.
Ideally the AUC for platinum in the plasma ultrafiltrate would be 
correlated with the AUC for the total plasma platinum and the amount of 
platinum excreted in the urine to give a fuller picture of its fate. In the clinical 
situation this would involve significant manipulations of the patient.
A simpler clinical assessment of exposure may be the concept of dose 
intensity described by G andara and others (1989). This can be easily calculated 
from reports of clinical trials.
The use of cisplatin in the therapy of osteosarcoma and associated metastatic 
disease in man and the dog
Cisplatin is a chemotherapeutic of major clinical importance in man. 
However, though it is used in the therapy of osteosarcoma it is used as a 
component of a multiple drug regime. The major clinical uses of cisplatin are in 
the treatm ent of germinal cell tumours and solid carcinomas of the head and neck.
Currently cisplatin is the most commonly reported chem otherapeutic agent 
used for the therapy of canine osteosarcoma. It is reported almost exclusively as a 
single agent. There is no doubt that the use of cisplatin significantly increases the 
survival of dogs affected by the tumour. However, ultimately all patients die or 
are euthanased as the result of metastatic disease (there are occasional reports of 
animals with an apparent cure).
Improvements in the benefits of this kind of therapy for osteosarcoma lie
with:
• assessing the tumour and its metastases for evidence of subsets with distinct 
biological behaviour
• improving the therapeutic index of cisplatin by the use of techniques such as
hypertonic saline and other protective measures particularly with reference to
myelosuppression
• introducing other drugs into the protocol
• assessing protocols by developing multi-centre prospective trials to increase
case accrual rates
• achieving a better understanding of the pharmacokinetics in the clinical 
setting and relating this to outcome
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• further investigation of the consequences of cisplatin chemotherapy on 
allografts used in the reconstruction of tumour resection sites
Though cisplatin does not, at present, prevent the inevitable consequences 
of canine osteosarcoma it does have positive benefits and it is likely that these can 
be improved by refinement of the administration protocol and dosing regime. For 
committed owners of affected animals, that are suitable for therapy, it is an option 
that should be considered and the ramifications carefully discussed.
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Appendices
Patient Platinum
identification (ng m l1)
117100 0.39
117113 0.64
117748 0.29
117740 0.58
117728 0.25
117677 0.47
113358 0.13
117482 0.34
117837 0.40
117844 0.00
mean 035
standard deviation 0.19
Table 35. Ultrafiltrable plasma platinum levels detected in 10 dogs hospitalised 
at Glasgow University Veterianry School and not exposed to cisplatin
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Start and end Sample Date and Time Pt
of infusion number time (minutes) (ng m l1)
1 11/10/90 15:25 0 2916.50
2 11/10/90 15:31 6 2216.50
3 11/10/90 15:36 11 1797.00
4 11/10/90 15:44 19 1288.50
5 11/10/90 15:56 31 833.00
6 11/10/90 16:39 74 161.50
7 11/10/90 17:28 123 60.50
8 11/10/90 19:28 243 32.50
9 11/10/90 21:26 361 32.00
10 11/10/90 23:23 478 31.00
11 11/10/90 3:27 722 24.50
12 11/10/90 15:25 1440 22.00
Table 36. Platinum in plasmsa ultrafiltrate for case number 114993.
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Start and end Sample Date and Time Pt
of infusion number time (minutes) (ng m l1)
1 22/11/90 16:02 0 0.55
4 22/11/90 16:04 2 1.60
5 22/11/90 16:06 4 76.64
6 22/11/90 16:09 7 248.94
7 22/11/90 16:12 10 362.23
9 22/11/90 16:17 15 796.02
10 22/11/90 16:21 19 838.40
11 22/11/90 16:24 22 882.37
12 22/11/90 16:27 25 744.77
13 22/11/90 16:31 29 538.75
14 22/11/90 16:35 33 516.40
15 22/11/90 16:41 39 449.89
16 22/11/90 16:51 49 305.48
17 22/11/90 17:27 85 111.90
18 22/11/90 18:24 142 88.71
19 22/11/90 20:30 268 21.75
20 22/11/90 21:30 328 16.80
21 22/11/90 23:37 448 15.68
22 23/11/90 01.34 512 16.08
23 23/11/90 15:00 1378 11.91
24 29/11/90 9:30 9688 4.47
25 6/12/90 9:00 19738 1.47
Table 36 (cont.). Platinum in plasma ultrafiltrate for case number 114993.
114
Appendices
Start and end Sample Date and Time Pt
of infusion number time (mins) (ng m l1)
start kO 13/12/90 14:53 0 3.10
kl 13/12/90 14:55 2 165.57
k2 13/12/90 14:58 5 349.96
k3 13/12/90 15:04 11 723.82
k4 13/12/90 15:09 16 904.35
k5 13/12/9015:16 21 1062.78
end k6 13/12/90 15:21 26 1249.80
k7 13/12/90 15:23 28 1176.67
k8 13/12/90 15:29 34 810.40
k9 13/12/90 15:31 37 743.41
klO 13/12/90 15:40 46 511.33
k ll 13/12/90 15:43 49 333.89
kl2 13/12/90 16:23 91 110.72
kl3 13/12/90 17:34 161 33.28
kl4 13/12/9018:32 212 29.37
kl5 13/12/90 20:29 329 20.00
kl6 13/12/90 22:25 452 19.87
kl7 14/12/90 00:28 576 21.18
kl8 14/12/90 2:20 688 19.87
kl9 14/12/90 15:38 1505 2.89
k20 19/12/90 8:56 destroyed
k26 467.02
k27 destroyed
k28 459.87
k29 282.70
Table 36 (cont.). Platinum in plasma ultrafiltrate for case number 114993.
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Start and end 
of infusion
start
end
Table 36 (cont.).
Sample
number
Date and 
time
Time
(minutes)
Pt
(ng m l1)
k2-l 10/1/9114:03 destroyed
k2-2 10/1/9114:05 2 200.14
k2-3 10/1/9114:10 7 534.16
k2-4 10/1/9114:16 13 962.95
k2-5 10/1/9114:25 22 953.74
k2-6 10/1/9114:28 destroyed
k2-7 10/1/9114:31 destroyed
k2-8 10/1/91 14:36 destroyed
k2-9 10/1/91 14:41 destroyed
k2-10 10/1/9114:58 destroyed
k2-ll 10/1/9115:52 37.53
k2-12 10/1/9116:27 39.20
k2-13 10/1/9118:33 6.40
k2-14 10/1/91 20:33 destroyed
k2-15 10/1/91 22:27 12.50
k2-16 11/1/91 2:23 740 12.28
k2-17 11/1/91 14:24 1461 15.98
rk l8 /l/91 18/1/91 9:29 4.75
rk25/l/91 25/1/91 9:30 3.05
rk31/l/91 31/1/91 15:50 1.41
rk 7/2/91 7/2/9111:10 1.27
Platinum in plasma ultrafiltrate for case number 114993.
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Start and end 
of infusion
Sample
number
Date and 
time
Time
(minutes)
Pt
(ng m l1)
si 20/12/90 14:37 0 0.65
s2 20/12/90 14:39 2 442.24
s3 20/12/90 14:42 5 1007.26
s4 20/12/90 14:47 10 1734.51
s5 20/12/90 14:53 16 2502.96
s6 20/12/90 14:56 19 1962.00
s7 20/12/90 15:02 25 1657.53
s8 20/12/90 15:06 29 1756.00
s9 20/12/90 15:11 36 430.00
slO 20/12/90 15:23 48 324.00
s l l 20/12/90 15:36 51 417.00
sl2 20/12/90 16:06 81 241.00
sl3 20/12/90 16:56 131 50.49
sl4 20/12/90 20:00 255 61.63
sl5 20/12/90 21:12 327 27.58
sl6 20/12/90 22:57 432 33.69
sl7 21/12/90 3:59 803 12.99
sl8 21/12/90 15:14 1477 8.04
sl9 27/12/90 10:25 9828 2.16
ks5/l/91 3/1/9112:05 20008 1.75
s2-l 11/1/9116:58 0 4.29
s2-2 11/1/9117:00 2 214.41
s2-3 11/1/9117:04 6 618.28
s2-4 11/1/9117:09 11 840.76
s2-5 11/1/9117:13 15 1340.69
s2-6 11/1/9117:23 25 1002.88
s2-7 11/1/91 17:26 28 834.07
s2-8 11/1/9117:29 31 destroyed
s2-9 11/1/9117:33 35 destroyed
s2-10 11/1/9117:38 40 destroyed
s2-ll 11/1/9117:53 55 destroyed
s2-12 11/1/9118:30 92 destroyed
s2-13 11/1/91 19:25 147 destroyed
s2-14 11/1/91 21:31 273 destroyed
s2-15 11/1/91 23:21 383 destroyed
s2-16 12/1/91 1:24 506 destroyed
s2-17 12/1/91 5:27 749 destroyed
s2-18 12/1/91 17:23 1465 destroyed
18/1/91 18/1/91 9:47 9660 4.22
1/2/91 1/2/9116:16 30198 1.03
start
end
start
end
Table 37. Platinum in plasma ultrafiltrate for case number 115930
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Start and end 
of infusion
Sample
number
Date and 
time
Time
(minutes)
A
Pt 
(ng m l1)
start vl 25/04/91 14-30 0 0.80
v2 25/04/91 14-32 2 239.29
v3 25/04/91 14-35 5 497.64
v4 25/04/91 14-40 10 860.46
v5 25/04/9114-45 15 1151.84
end v6 25/04/9114-48 18 1597.25
v7 25/04/91 14-52 22 1149.07
v8 25/04/9114-56 26 938.50
v9 25/04/9114-58 28 774.39
vlO 25/04/9115-04 34 637.81
v ll 25/04/91 15-18 48 380.28
vl2 25/04/91 15-48 78 138.03
vl3 25/04/91 16-48 138 40.96
vl4 25/04/91 19-00 150 10.03
vl5 25/04/91 20-48 258 8.75
vl6 25/04/91 23-12 382 7.85
vl7 26/04/91 02-58 748 6.53
vl8 26/04/91 15-06 1476 5.91
1 week post vl9 02/05/91 09-30 8340 1.52
2 weeks post v20 09/05/91 09-15 19795 0.65
start v21 16/05/9115-20 30290 1.32
v22 16/05/9115-23 30293 369.88
v23 16/05/9115-27 30297 6.84
v24 16/05/9115-31 30301 878.44
v25 16/05/91 15-36 30306 1152.73
v26 16/05/91 15-42 30312 1613.47
end v27 16/05/91 15-54 30324 2078.36
v28 16/05/91 15-57 30327 1728.84
v29 16/05/9116-00 30330 1017.35
v30 16/05/9116-06 30336 1006.49
v31 16/05/9116-10 30340 938.80
v32 16/05/91 16-15 30345 724.47
v33 16/05/91 16-25 30355 518.46
v34 16/05/91 16-58 30388 134.89
v35 16/05/9118-01 30451 49.72
v36 16/05/91 20-00 30570 32.04
v37 16/05/91 22-00 30690 27.39
Table 38. Platinum in plasma ultrafiltrate for case number 116799.
118
Appendices
Start and end Sample Date and Time Pt
of infusion number time (minutes) (ng m l1)
v38 17/05/91 00-04 30814 25.46
v39 17/05/91 04-00 31050 18.11
v40 17/05/9116-43 31813 15.51
1 week post v41 23/05/91 09-17 40007 4.51
2 weeks post v42 30/05/91 09-30 50100 2.81
3 weeks post v43 06/06/9112-00 60330 1.13
v44 10/06/91 09-30 65940 1.04
6 weeks post v45 26/06/9110-00 89010 1.49
Table 38(cont.). Platinum in plasma ultrafiltrate for case number 116799.
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